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Chapter 1 
1.1 Atherosclerosis. 
 
 The prime cause of mortality in the Western world involves cardiovascular diseases 
(CVD) such as myocardial or cerebral infarction. Illustratively, in the Netherlands, CVD account 
for 34% of all deaths (Statistics Netherlands CBS, 2002). The underlying process leading to these 
disorders is the development of atherosclerosis which is characterized by endothelial dysfunction, 
vascular inflammation, and the progressive accumulation of lipids, cholesterol, calcium, and 
cellular debris in the intima of the vessel wall (“the plaque”). Atherosclerosis occurs mainly in 
large and medium sized elastic and muscular arteries and may result in vascular remodeling, 
acute and chronic luminal obstruction, abnormalities of blood flow and diminished oxygen 
supply to distal target organs. The processes that contribute to atherosclerosis appear to be 
multifactorial. At present, the response-to-injury theory in which endothelial injury causes a 
vascular inflammatory and ensuing fibroproliferative response is most widely accepted 1,2. 
Identified risk factors that can inflict such an injury include hypertension, elevated blood 
cholesterol levels, high stress levels, diabetes mellitus, cigarette smoking, obesity, and lack of 
exercise. Endothelial injury often is accompanied by permeability to lipoproteins and migration 
of monocytes and T-lymphocytes to the site of injury. The extravasated monocytes differentiate 
into macrophages and subsequently, start to accumulate lipids from circulating lipoproteins 
leading to the development of so-called foam cells, a hallmark event in atherosclerosis. With 
regard to atherosclerosis, high serum lipid levels contribute considerably to the rate and extent of 
subendothelial retention of lipids and hyperlipidemic patients thus form a high-risk group for 
cardiovascular diseases. 
 
1.2 Lipid Metabolism 
 
Cholesterol and triglycerides are the most common dietary lipids and essential for 
membrane structure, synthesis of steroid hormones, vitamins, bile acids, and energy-storage. 
Although cholesterol is absorbed from the diet, the body itself can produce sufficient amounts of 
cholesterol and normally contributes over 50% of daily required cholesterol 3. Cholesterol is a 
vital component of the plasma membranes as it determines the fluidity of lipid bilayers. 
Cholesterol is also essential in the biosynthetis of vitamin D, bile acids, and steroid hormones 
10 
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such as testosterone, estradiol, and cortisol. Triglycerides play a central role as energy supply for 
skeletal and cardiac muscles. 
 Lipids are transported through the body via blood and lymph. To this end the hydrophobic 
cholesterol (-esters) and triglycerides are assembled in lipoprotein particles, which are 
macromolecular complexes with a hydrophobic core containing the cholesterol esters and 
triglycerides. To render it soluble in an aqueous environment, the lipid core is surrounded by a 
monolayer of polar phospholipids which also contains unesterified cholesterol and proteins called 
apolipoproteins (table I). Apolipoproteins serve as ligands for cell-surface receptors and co-
factors/inhibitors of lipases and other enzymes. 
 
Table1. Apolipoproteins associated with lipoproteins 
apolipoprotein Lipoptrotein association Comments 
   
apoA1 Chylomicron, HDL Major protein of HDL, activates LCAT  
 
apoA2 Chylomicron, HDL Enhances hepatic lipase activity 
 
apoA4 Chylomicron, HDL Co-factor for LPL activation, may have a role in 
chylomicron and VLDL secretion and catabolism, 
activates LCAT 
 
apoA5 HDL Activates LPL 
 
apoB48 Chylomicron Exclusively found in chylomicrons, alternative splice 
product of the apoB100 gene thereby lacking the LDL 
receptor-binding domain 
 
apoB100 VLDL, IDL, LDL Ligand for the LDL receptor 
 
apoC1 Chylomicron, VLDL, IDL, HDL Appears to modulate the interaction of apoE with β-
VLDL and inhibit binding of β-VLDL to LRP 
 
apoC2 Chylomicron, VLDL, IDL, HDL Activates LPL 
 
apoC3 Chylomicron, VLDL, IDL, HDL Inhibits LPL 
 
apoE Chylomicron, VLDL, IDL, HDL Ligand for LDL receptor and LRP 
 
 
Based on their size, and lipid and apolipoprotein composition, lipoproteins can be 
categorized into five classes: chylomicrons, very low density lipoprotein (VLDL), intermediate 
density lipoprotein (IDL), low density lipoprotein (LDL), and the high density lipoprotein 
(HDL). However, heterogeneity exists within each class because of the constant remodeling of 
their composition, shape, size, and surface charge, and exchange of protein and lipid constituents. 
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The liver plays a central role in lipid metabolism. Lipoprotein trafficking from and to the 
liver proceeds along two pathways: the endogenous and the exogenous pathway Cholesterol 
transport from peripheral tissues to the liver is often considered as the third pathway.  
 
1.2.1 Exogenous and Endogenous pathway 
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1igure 1. Schematic illustration of metabolic pathways of lipid metabolism. Adapted from Dr. K. Willems van Dijk.
 
The exogenous pathway involves the uptake of dietary lipids by the intestine followed by 
heir transport through the body via lipoproteins (Fig.1). After the lipid intake, the triglycerides 
nd the cholesteryl esters will be hydrolyzed in the intestine and subsequently assembled into 
hylomicrons. These large triglyceride-rich chylomicrons containing apoA1, apoA2, apoA4, and 
poB48 are secreted into the lymph in order to transport entrapped lipids to the circulation. In the 
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bloodstream, the chylomicrons exchange apoA1 and associated apoA4 for apoC1, apoC2, apoC3, 
and apoE with HDL which subsequently results in the formation of the more cholesterol-rich 
chylomicron remnants due to loss of triglycerides to peripheral tissue. ApoC2 is an activator of 
the lipolytic enzyme lipoprotein lipase (LPL), which is associated with the capilairy endothelium 
of skeletal muscle, cardiac muscle, and adipose tissue 4. ApoC2 aided interaction of chylomicrons 
with LPL allows the lipolysis of its core triglycerides leading to the formation of free fatty acids 
which are taken up by surrounding tissue for further use. Lipolysis gradually becomes less 
efficient due to depletion of the LPL co-activator apoC2. Eventually the chylomicron remnants, 
enriched in cholesteryl esters, apoB48, and apoE, are eliminated from the circulation by the liver 
mainly via the uptake by the LDL-receptor which specifically recognizes apoE and apoB100, and 
by the LDL-receptor related protein (LRP) 5,6. 
The liver produces the triglyceride-rich lipoprotein, VLDL, which is introduced into the 
endogenous pathway. Some of the VLDL contained triglycerides will be derived from 
internalized chylomicron remnants, but the bulk of the VLDL triglycerides are synthesized de 
novo in the liver from fatty acids produced from dietary carbohydrate derived Acetyl-CoA 7. The 
formation of VLDL starts with the transfer of lipids towards the major structural protein of 
VLDL, apolipoprotein B100 (apoB100). This transfer is catalyzed by the microsomal triglyceride 
transfer protein (MTP), making this enzyme a key factor in the assembly of VLDL. Subsequently 
before secretion into the blood circulation, the pre-VLDL particle acquires apoC1, apoC2, apoC3, 
and ApoE. ApoE plays a critical role when it comes to secretion of VLDL and clearance of 
VLDL remnants, 8. Similar to chylomicrons, VLDL transports triglycerides to skeletal muscle, 
cardiac muscle, and adipose tissue and also serves as substrate for LPL lipolysis in the 
circulation. As a result, VLDL particles gradually reduce in size due to hydrolysis of the 
triglycerides leading to the formation of the more cholesterol-rich IDL. Small sized VLDL and 
IDL are also referred to as VLDL remnants. These remnants are partially cleared by the liver 
through an apoE-mediated process while the remainder can be converted to LDL 9-11. The 
conversion to LDL is accompanied not only by a further loss in triglycerides but also by the 
depletion of apoE and the apoC’s. With apoB100 as sole apolipoprotein constituent of LDL, LDL 
can be cleared by the liver or taken up by peripheral tissue via the LDL receptor. High levels of 
LDL and/or VLDL remnants are considered as important risk factors for atherosclerosis 12, and 
are therefore also termed atherogenic lipoproteins. 
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1.2.2 Reverse cholesterol transport 
 
While the first two pathways focuses mainly on the transport of triglycerides from 
intestine and liver to peripheral tissue via apoB-containing lipoproteins followed by the clearance 
of cholesterol-rich lipoprotein remnants, the third pathway involves the net transport of (excess) 
cholesterol from peripheral tissue back to the liver where it can be removed from the body via the 
bile by conversion to bile acids or as biliary cholesterol (Fig 1). The reverse transport of 
cholesterol is mediated by the lipoprotein HDL, of which the metabolism is complex and only 
partially understood. HDL is a heterogeneous class of lipoprotein particles existing of different 
subfractions that differ in e.g. apoliprotein and lipid composition, size, density, and even 
physiologic function. However, apoA1 plays a key role in the biogenesis and function of all HDL 
subclasses 13,14. Generation of HDL starts with the intestinal and hepatic synthesis and secretion 
of lipid-poor apoA1. This ApoA1 ‘particle’ acquires phospholipids and unesterified cholesterol 
from cell membranes and plasma lipoprotein to convert into a discoidal preβ-HDL particle. Both 
nascent pre-HDL particles are potent cholesterol acceptors and take up free cholesterol from 
peripheral cells and, importantly from an cardiovascular point of view, macrophages. This 
cholesterol efflux is mediated by the integral membrane protein ATP-binding cassette transporter 
A-1 (ABCA1), which actively transports cellular cholesterol (and phospholipids) to the nascent 
HDL 15,16. The importance of ABCA1 in reverse cholesterol was established in patients with 
Tangier disease, who are characterized by HDL deficiency. This disease is caused by a 
dysfunctional ABCA1 and  results in massive accumulation of cholesterol in tissue macrophages 
and prevalent atherosclerosis 17-19. Cholesterol taken up by the nascent HDL particles will be 
esterified by the enzyme lecithin:cholesterol acyltransferase (LCAT), transforming nascent preβ-
HDL into larger spherical HDL-particles. Subsequently, the latter HDL particles are subjected to 
remodeling after interaction with other plasma lipoproteins or tissues. For instance, the 
cholesteryl ester transfer protein (CETP) catalizes the exchange of cholesteryl esters for 
triglycerides with apoB-containing lipoproteins. The uptake of HDL cholesterol by the liver is 
mainly mediated by the scavenger receptor class B1 (SR-B1). Once in the liver, cholesterol can 
be re-used for lipoprotein assembly, used as substrate for bile acid synthesis, or secreted directly 
as free cholesterol into the bile.  
14 
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Although during the last years classifications of the different stages of HDL have become 
as intricate as the particle itself due to the various compositions, sizes, functions, ect., it is 
becoming increasingly clear that HDL plays a significant role in cholesterol homeostasis. 
Particularly the role of HDL in reverse cholesterol transport and the athero-protective 
characteristics of this particle are widely accepted 20. 
 
1.3 Genetic factors in dyslipidemia 
 
The expression of lipid-related genes under normal conditions is tightly coordinated in 
order to maintain lipid homeostasis. Unfortunately, in western societies and in emerging 
economies a large part of the population suffer from a perturbed lipid homeostasis resulting in 
unbalanced plasma levels of the different lipoproteins and an increased incidence of coronary 
events and cardiovascular deaths. Although factors such as a high cholesterol consumption and 
increasing age are important, undesirable lipoprotein profiles are also determined by genetic 
factors such as dysfunctional genes. 
Familial hypercholesterolemia (FH), one of the most common causes of 
hypercholesterolemia, was the first genetic disease of lipid metabolism to be characterized 21,22. 
Patients suffer from elevated plasma levels of LDL-cholesterol caused by mutations in the LDL-
receptor gene. To date, well over 500 mutations of the LDL-receptor have been identified 23. The 
severity of the hypercholesterolemia depends on the nature of the molecular defect and whether 
the mutation is homo- or heterozygous. Patients with homozygous FH develop significant 
atherosclerotic heart disease at a relative early age 24. The clinical prognosis of patients with 
heterozygous FH is related not only to the magnitude of the elevation in plasma LDL-cholesterol 
levels, but also to the presence of other cardiovascular risk factors 25. 
A disease that shows similarity with FH in that it also results in a reduced uptake of LDL 
by the LDL-receptor is familial defective apoB100 (FDB). This disease is caused by several 
mutations in apoB100 at the postulated binding site to the LDL-receptor 26-28. However, the  
phenotype of patients homozygous for FDB generally is less severe than that of FH patients 29. 
The latter is the result of a reduced formation rate of LDL particles in the plasma, since FDB 
patients are still able to clear the LDL precursor particles (VLDL, IDL, and their remnants) via 
apoE mediated uptake 30. 
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Polymorphisms in lipid related genes, such as apoE, also predispose to cardiovascular 
diseases. Three major apoE isoforms, E2, E3, and E4, are encoded by three common alleles at the 
apoE gene locus: ε2, ε3, and ε4 31,32. The apoE2 isoform is associated with lower and that of 
apoE4 with elevated total plasma- and LDL-cholesterol levels than the more common apoE3 
isoform. These three isoforms differ in their affinity for the LDL receptor which can influence the 
serum profile and levels of apoE containing lipoproteins. For example, the majority of patients 
with type III hyperlipidemia, which is characterized by elevated levels of cholesteryl ester 
enriched remnant particles, appear to be homozygous for apoE2 33. The apoE4 allele, which is 
receiving great attention due to its linkage to Alzheimer's disease, is associated with an increased 
prevalence for cardiovascular disease especially in populations consuming diets rich in saturated 
fat and cholesterol 34. 
Many other, mostly rare, single lipid-related gene mutations such as the ABCA1 
mutations found in patients with Tangier disease discussed earlier, have been described. 
However, these and the aforementioned examples are of monogenic nature and, with the 
exception of FH, show a low frequency. Dyslipidemia being a multifactorial process, the major 
portion of this predisposition is polygenic, reflecting cumulative effects of multiple genetic 
sequence variants. These hereditary factors are difficult to identify since possible dyslipidemia 
phenotypes are the result of complex interactions between genetic and environmental factors (ref, 
Corella D and Ordovas JM, 2004). 
 
1.4 Central role of the liver in lipid metabolism 
 
As indicated above, maintenance of lipid homeostasis is the sum of numerous complex 
physiological processes both at an organ, and at a cellular level. The organ that plays a key role in 
the synthesis and catabolism of lipids is the liver (Fig.2). It expresses enzymes that are 
responsible for synthesis (e.g. fatty acid synthetase and HMG-CoA reductase) of triglycerides 
and cholesterol (esters). Excess of cholesterol can be metabolized in the liver via enzymes such 
as cholesterol-7-α-hydroxylase and sterol 27-hydroxylase (cyp7A1 and cyp27, respectively), and 
removed from the body via bile acid synthesis. Further, it is involved in assembly and secretion 
of the main lipoproteins, i.e. VLDL and HDL, and the elimination of serum lipoproteins via 
lipoprotein receptors. Most, if not all, apolipoproteins involved in the metabolism of lipoproteins 
16 
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are expressed in the liver. In order to prevent high lipid levels, which correlate with increased risk 
of cardiovascular disorders, it is essential that the expression of lipid-related genes in the liver is 
well orchestrated. Several aspects and processes will be highlighted below. 
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 igure 2. The liver plays a central role in maintaining lipid homeostasis.   
.4.1 Lipoprotein synthesis 
Via the formation of triglycerides-rich lipoproteins in the liver, lipids are distributed 
hroughout the body. Hepatic assembly and secretion of apoB-containing VLDL requires a 
emporary pool of lipids to form the monolayer surface (mainly phosphatidyl choline and 
holesterol) and the neutral lipid core, the production of the structural protein apoB, and the rate 
imiting enzyme MTP 35,36. The lipid pool used for VLDL synthesis is fed by two sources: uptake 
f dietary lipids and de novo synthesis.  
Important rate limiting enzymes for the synthesis of fatty acids are acetyl-CoA 
arboxylase and fatty acid synthase, while the enzymes HMG-CoA synthase and HMG-CoA 
17
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reductase are major check points in cholesterol synthesis 37,38. The availability of lipids and rate 
of lipid biosynthesis, lipogenesis, influence the rate of VLDL assembly and secretion. 
The structural protein of VLDL is apoB. ApoB exists in two forms: the full length 
apoB100 and a truncated protein that contains only 48% of the full length version, apoB48. 
ApoB48 is the result of post-transcriptional modification of apoB100 mRNA by a cytidine 
deaminase (apobec1) containing enzyme complex 36,39,40. In humans, apobec1 is solely active in 
the intestine, and unlike rodents, no hepatic apobec1 expression can be found 41. Hence, VLDL 
particles synthesized in human liver only contain apoB100. Although apoB100 is the major 
apolipoprotein of VLDL, a significant portion of newly synthesized apoB is degraded 
intracellular via several possible proteasomal and non-proteasomal processes prior to secretion 42-
44. Studies showing that an increased apoB100 secretion is not accompanied by a detectable 
change in apoB mRNA, support the notion that apoB100 production is regulated at a post-
transcriptional level by means of degradation (44-46. The underlying mechanisms of degradation 
and its regulatory control have not been completely elaborated, but it has become clear that 
premature degradation can be prevented by translocation across the endoplasmic reticulum (ER) 
and subsequent lipidation of the nascent apoB100. The protein crucial for these processes is 
MTP, which resides in the lumen of the ER as a heterodimer with the ubiquitous ER-enzyme, 
protein-disulfide isomerase. The latter seems to be required by MTP for its solubility, ER 
retention, and for lipid-transfer-activity of MTP 47,48. In the ER, MTP binds to newly synthesized 
lipid-poor apoB and facilitates the transfer of triglycerides, cholesterol esters, and phospholipids. 
Recent studies indicate that during the lipidation process the affinity of MTP for apoB decreases, 
allowing at a certain point the dissociation of MTP from ApoB, and the formation of a secretion-
competent primordial VLDL 49. Based on findings with conditional liver-specific MTP gene 
knockout mice, specific MTP inhibitors, and hepatic MTP overexpression in mice, MTP is 
considered to be the rate-limiting enzyme in the VLDL assembly/secretion pathway 50-53. 
 
1.4.2 Gene clusters of essential apolipoproteins 
 
After lipidation and upon secretion, the nascent VLDL acquires apoEs and apoCs in the 
bloodstream and matures into an apoE, apoC1, apoC2, apoC3 containing VLDL with a single 
copy of apoB100. Interestingly, all of these apolipoproteins, except for apoB100, are genetically 
18 
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located in two gene clusters: the apoE/C1/C4/C2 and the apoA1/C3/A4/A5 gene cluster (Fig. 3). 
Besides having their own proximal promoters the genes in each cluster share common regulatory 
regions and therefore are under a tight transcriptional control 54,55. 
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igure 3. A schematic of the apoE/C1/C4/C2 and the apoA1/C3/A4/A5 gene clusters. The genomic organization 
f the apoE/C1/C4/C2 gene cluster is largely conserved between mouse and human with the exception that in mouse 
here is no duplication of the genomic region containing ME.1, apoC1, and HCR.1. In humans, this duplication gives 
ise to ME.2, the speudogene apoC1’, and the HCR.2. 
 
In the human apoE/apoC1/apoC4/apoC2 gene cluster common enhancer regions called 
epatic control regions-1 en -2 (HCR-1 and HCR-2) have been identified, which appear to be 
ecessary  for a coordinate liver-specific expression 56. The HCR-2 has 85% sequence identity to 
he HCR-1, and is likely the result of an evolutionary duplication of the genomic region 
ontaining apoC1 and HCR-1 since the conserved gene cluster in mice lacks HCR-2 57,58. 
lthough each HCR can individually orchestrate the expression of all four genes, it seems that 
CR-1 has a dominant effect on the expression of apoE and apoC1, while vice versa HCR-2 
ontrols the expression of apoC4 and apoC2. Removal of both control regions, however, almost 
ompletely ablates the expression of all four genes 56. Recently two homologous enhancers, 
istinct from the HCRs and designated multienhancer-1 and -2 (ME.1 and ME.2), have been 
dentified in the apoE/apoC1/apoC4/apoC2 cluster 59. Both enhancers were found to be involved 
n the control of gene expression in non-hepatic cells such as macrophages and adipocytes 60,61. 
For the apoA1/C3/A4/A5 gene cluster coordinated expression is more complicated, but 
everal studies have established that the hepatic transcription of the first three genes in the gene 
19
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cluster are regulated by a common enhancer located upstream of the apoC3 54,62. Although the 
first characteristics of the proximal promoter of the most recently identified member of the gene 
cluster, apoA5, have been described, its control has to date not been linked to the upstream 
members of the gene cluster 63 
 
1.4.3 Hepatic uptake and removal of cholesterol 
 
As described above, cholesterol-rich remnants and HDL are cleared from the plasma via 
hepatic receptors. The main receptors responsible for the uptake of chylomicron- and VLDL-
remnants, and LDL are the LDL receptor and LRP 64,65. Given the importance of the reverse 
cholesterol pathway in lipid homeostasis, the identification of the HDL-receptor, scavenger 
receptor class B type 1 (SR-B1), was a breakthrough. SR-B1 is a cell-surface transmembrane 
protein which functions as a high affinity receptor for HDL 66, but also can bind a wide variety of 
other ligands including LDL and VLDL 67. Not only does SR-B1 bind HDL, but it also mediates 
selective lipoprotein cholesterol uptake 68. This selective uptake involving cholesterol delivery 
from plasma HDL to the liver without particle degradation does not require co-factors 69,70. Upon 
cholesterol uptake, the cholesterol can be stored in the liver after conversion to cholesteryl esters 
by acyl-CoA:cholesterol acyltransferase (ACAT). The intracellular cholesterol pool can be re-
used for assembly of VLDL or eliminated from the liver via bile directly or via bile acid 
synthesis. 
Direct secretion of cholesterol into the bile proceeds through two ATP-binding cassette 
(ABC) transporters, ABCG5 and ABCG8 71-73. These ATP dependent sterol transporters function 
as obligate heterodimers to promote sterol excretion into the bile 74. Conversion of cholesterol 
into bile acid involves a cascade of reactions and almost 20 different enzymes have been 
identified. Basically, at present two pathways exist for bile acid synthesis 75. The classical neutral 
pathway, which is the main route, involves the rate-limiting enzyme cholesterol 7α-hydroxylase 
(cyp7A1), and leads to the production of mainly cholic acid. The alternative pathway or acidic 
pathway is initiated by the enzyme sterol 27-hydroxylase (cyp27) which preferentially produces 
chenodeoxycholic acid. Both bile acids can be transported into the bile after which the bile acids 
are secreted into the intestine to leave the body or to be re-absorbed. 
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1.4.4 Regulators of lipid-related genes 
 
With the identification of the hepatic enzymes and the structural components involved in 
lipid metabolism, the attention of scientific research has shifted towards the the regulatory control 
of lipid metabolism. The last years more insight has been obtained in the direct effect that several 
lipid-related processes have on hepatic gene transcription. Especially studies demonstrating that 
lipids and their metabolites can act as ligands for transcriptional regulators have become of great 
interest. 
One of the first transcription factors which was found to have a central role in controlling 
hepatic gene expression was the hepatic nuclear receptor HNF-4 76. Studies with conditional 
HNF-4 knockout mice showed that this transcription factor is involved in the control of a wide 
array of genes 77. These knockout mice showed reduced VLDL secretion due to decreased 
expression of MTP and apoB100 and an increased uptake of HDL due to increased expression of 
SR-B1.  In addition, also the apolipoprotein genes found in the two gene clusters were seen to be 
HNF-4 responsive 55. Interestingly, the transcriptional activity of HNF-4 is modulated via binding 
of fatty acids 78,79. 
Transcription of genes involved in the synthesis of fatty acids, triglycerides, and 
cholesterol are is in part orchestrated by the sterol regulatory element-binding proteins (SREBPs) 
80. SREBP-1c is involved in fatty acid metabolism, whereas SREBP-2 plays a major role in 
regulation of cholesterol synthesis. The SREBPs are synthesized as precursor proteins bound to 
the ER membrane and nuclear envelope. The transcriptionally active N-terminal domain SREBP 
must be released from the membrane to enter the nucleus and transactivate response genes. This 
release is mediated by the SREBP chaperone, cleavage–activating protein (SCAP) which acts as a 
sterol sensor. When cells become depleted in cholesterol, SCAP will escort the SREBP to the two 
proteases that are responsible for cleavage. Conversely, this proteolytic process is blocked when 
the cells are overloaded with sterols.  
Recently, a specific group of nuclear receptors, the orphan receptors, has received great 
attention. Prior to DNA binding and gene activation, these receptors need to form heterodimeric 
complexes with retinoid X receptor (RXR). Members of this group include the peroxisome 
proliferator-activated receptors (PPARs), the liver X receptors (LXRs), and the farnesoid C 
receptors (FXRs) (Fig. 4). 
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igure 4. Nuclear receptors PPAR, LXR, and FXR form heterodimeric complexes with RXR and affect lipid 
elated genes. The ligands that activate the indicated nuclear receptor are shown in the cartoon on the left. The 
atural ligand for RXR is 9-cis retinoic acid (9-cis RA). Some of the genes involved in lipid metabolism affected by 
hese nuclear receptors are listed on the right.   
The PPAR family consists of three members: PPARα, PPARγ, and PPARδ (also called 
PARβ). These three subtypes bind fatty acids and fatty acid metabolites and regulate the 
xpression of genes involved in the transport, metabolism and storage of these ligands within 
ells 81. Whereas PPARδ is abundantly expressed throughout the body, PPARγ and PPARα are 
ainly expressed in adipose tissue and in liver, respectively 81. The initial finding that PPARs 
an be activated by fibrates, a class of cholesterol lowering agents, gave more insight into the 
unction of these nuclear receptors and helped to identify target genes 82-84. In the liver, PPARα 
lays a key role in the uptake of free fatty acids and in fatty acid catabolism. Triglyceride 
learance by the liver is increased by the PPARα dependent activation of genes such as LPL 85. 
urthermore, PPARα leads to an inhibition of apoC3, a natural inhibitor of LPL activity, and an 
2 
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induction of apoA5, an inducer of LPL activity, resulting in a further decrease in serum 
triglycerides 63,86-90. Through the PPARα induced upregulation of genes involved in β-oxidation 
of fatty acids, the pool of fatty acids available for triglyceride synthesis and incorporation into 
VLDL will be further diminished 84,91. PPARα also influences reverse cholesterol transport at 
different levels in a species-specific manner. In humans for instance, PPARα enhances the 
expression of apoA1, which leads to increased plasma HDL levels, while in mice the opposite 
seems to be the case 92. 
LXR plays an essential role in cholesterol homeostasis throughout the whole body and 
serves as a cholesterol sensor that stimulates the expression of multiple genes involved in the 
efflux, reverse transport, and excretion of cholesterol 93. Hence, LXR is considered a potentially 
important therapeutic target to prevent atherosclerosis. There are two highly conserved isoforms 
of LXR, LXRα and LXRβ 94, which are both activated by mono-oxidized derivatives of 
cholesterol called oxysterols 95,96. LXRα is highly expressed in the liver and, based on the effects 
seen in LXRα-null and LXRβ-null mice, it appears to be the most crucial regulatory factor 97-99. 
Among the hepatic LXR target genes that have a beneficial effect on cholesterol metabolism are 
ABCG5, ABCG8, and SR-B1 71,100. Furthermore, LXR reduces cholesterol synthesis by 
repressing the expression of the enzymes HMG-CoA reductase and synthase and their 
transcriptional regulator SREBP-2 98,101. In rodents, LXRα also promotes the conversion of 
cholesterol to bile acids due to enhanced expression and activity of the cyp7A1 gene 96,98. 
Interestingly, activation of LXRα does not lead to enhanced cyp7A1 activity in humans 102,103. 
Besides cholesterol metabolism, LXR also regulates fatty acid synthesis. In fact, the synthesis of 
fatty acids is induced by LXR via the activation of SREBP-1c 101,104. 
The third member of this nuclear receptor family, FXR, acts as a bile acid sensor that 
protects the body from cytotoxic levels of bile acids and is activated by bile acids such as 
chenodeoxycholic acid and cholic acids 105. Upon activation, FXR upregulates genes involved in 
the transport of bile acids to the intestine such as ABCB11 (bile salt efflux pump, BSEP) 106. 
FXR also affects the bile acid synthesis by repressing cyp7A1 and thus prevents a further build 
up of bile acids 107-109. Besides its effect on bile acid metabolism, FXR activation lowers serum 
triglyceride levels by attenuating SREBP-1c expression 110. A recent report has also suggested the 
involvement of FXR in the repression of MTP 111. Like PPARα, FXR stimulates lipolysis by 
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affecting the expression of apoC2, apoC3, and apoA5 63,112,113. Finally, down-regulation of apoA1 
expression by FXR demonstrates that FXR also modulates HDL metabolism 114. 
The identification of the aforementioned transcription factors and their target genes 
contributes to a better understanding of the different hepatic and non-hepatic processes involved 
in lipid metabolism and their regulatory control. However, with the completion of the human 
genome project and subsequent genetic studies, even more genes with possible involvement in 
lipid metabolism are being identified. Among these novel genes are new putative regulators of 
transcription. One such factor is the zinc finger protein 202 (ZNF202), which was identified in 
the locus linked to heritable hypoalphalipoproteinemia in Utah pedigrees 115. Biochemical 
analysis showed that ZNF202 functions as a transcriptional repressor of target genes from both 
apolipoprotein gene clusters, and of ABCA1 116. In vitro studies confirmed the repressive effect 
of ZNF202 on the expression of apoE, apoA4, and ABCA1, and established its assumed role in 
HDL-metabolism by showing that ZNF202 is inversely regulated in macrophages with apoE and 
ABCA1 expression 116-118. How ZNF202 affects lipid homeostasis and its specific role in 
metabolic disorders remains to be clarified.  
 
1.5 Current treatment of hyperlipidemia 
 
A reduction in plasma lipid levels is generally thought to be associated with a substantial 
reduction in cardiovascular events. The treatment of hyperlipidemia can roughly be divided into 
two strategies: reduction of the atherogenic apoB-containing lipoproteins or induction of the 
reverse cholesterol transport.  
The former can be achieved by lifestyle changes such as a change of diet. However for 
patients with inherited hyperlipidemia these measures might not be adequate. With our increasing 
knowledge of the molecular mechanisms underlying cardiovascular disease, specific lipid-
lowering agents have been introduced. Notably the statins, potent HMG-CoA reductase inhibitors 
which lower hyperlipidemia by upregulating LDL receptors, have demonstrated their success and 
are to date the most commonly prescribed drugs against hyperlipidemia 119,120. A number of drugs 
have been designed that can increase HDL levels and thus stimulate reverse cholesterol transport 
such as fibric acid derivatives (PPAR agonists) or nicotinic acid 121. 
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MTP inhibitors that will directly influence the production of apoB-containing lipoproteins 
are under investigation at a pre-clinical level 51,52,122,123. However, several studies with MTP 
inhibitors have shown that their application may incidentally be accompanied by steatosis and 
deficiency of lipid soluble vitamins 50,124,125. LXR agonists are also being explored at present due 
to their athero-protective and possibly lipid regulating activity 126. Yet, these agonists are not 
without side-effects, such as an up-regulation of fatty acid synthesis leading to increased plasma 
triglyceride levels 104,127,128. 
Apart from this, the effectiveness of the current approaches for the treatment of lipid 
disorders vary per patient which can in part be attributed to interindividual genetic variation 
129,130. The remarkable advance in genomics has opened new entries for therapeutic approaches to 
interfere with hyperlipidemia in a more specific manner and it is expected that this might reduce 
the variable outcome of lipid lowering therapy. 
 
1.6 Modulation of Gene Expression in the liver as a therapeutic approach. 
 
Due to better understanding of lipid-related processes and the identification of genes with 
pro- or anti-atherogenic properties, potential new targets for gene and drug therapy are emerging 
and are currently being explored in appropriate in vitro and in vivo models. With the liver being 
the central organ in lipid metabolism, liver-directed gene therapy is certainly a primary target for 
future clinical treatment. Deficient or dysfunctional gene products such as apoE leading to 
elevated serum levels of apoB-containing lipoproteins could be replaced by transferring genes 
expressing those proteins 131,132. In other cases, protective genes such as apoA1 could be 
overexpressed for therapeutic purposes to favor HDL-metabolism 133. In some cases, proteins that 
are normally expressed at extrahepatic sites could be expressed in the liver for specific purposes. 
For instance, the introduction of APOBEC-1 to the liver to switch the hepatic apolipoprotein 
production from apo B100 to apo B48, thereby reducing the production of LDL, has been studied 
134,135. 
Instead of replacing or supplementing genes, nucleic acids may be used to attenuate or 
even inhibit the expression of genes such as MTP. In this regard, new gene silencing tools which 
include antisense oligonucleotides, ribozymes or more recently inhibitory double-stranded RNA 
(RNA interference, RNAi) have received great attention 136,137. These inhibitors of gene 
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expression can be introduced as synthetic oligonucleotides, but ribozymes and RNAi drugs can 
also be transferred into the liver via expression constructs and subsequently expressed via the 
endogenous transcription machinery to accomplish sustained inhibition. 
 
 
F
a
p
t
g
i
u
u
t
l
p
2 
igure 5. Antisense based strategies to knockdown expression of target genes. Gene silencing tools such as 
ntisense oligonucleotides, ribozymes, and RNA interference prevent the translation of transcribed mRNA to 
roteins via Watson-Crick based hybridization of short complementary sequences to their target mRNA.  
 
Although numerous targets and approaches have been proposed, a great concern is the 
issue specificity and therapeutic control of gene therapy. To increase the tissue specificity of 
ene delivery, targeting of viral and non-viral carriers to cell specific surface receptors is being 
nvestigated 138-140. Once arrived in the appropriate cells, it is preferable that these genes are 
nder tight control. Moreover, the use of tissue specific and inducible promoters will reduce 
ndesirable effects of long-term expression of transgenic genes 141. 
In conclusion, modulation of hepatic gene expression can be a powerful therapeutic tool 
o treat lipid disorders. However, despite the increased knowledge of the molecular mechanism of 
ipid metabolism, the effects of gene therapy-based intervention should be carefully monitored, in 
articular when aiming at a modulation of regulatory factors with a broad activity profile.  
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1.7 Outline of this thesis 
 
In this thesis we have evaluated the potential of two gene therapeutic targets for lipid 
lowering. First, we describe the development of antisense-based drugs against MTP, the rate 
limiting enzyme in VLDL synthesis. Antisense based knock-down of this gene should lead to a 
reduction of apoB-containing lipoproteins and a correction of the hyperlipidemic phenotype. In 
the second part of this thesis, we will address the role of the recently discovered Znf202 in lipid 
metabolism and its potential as therapeutic target in vivo. 
The pro-atherogenic nature of elevated serum levels of LDL is well established 1,12. 
Interfering with the hepatic apoB-containing lipoprotein synthesis will result in a reduction of 
plasma LDL levels. The fact that MTP is a rate-limiting factor in the VLDL-assembly makes it an 
attractive target for lipid lowering therapy 142. In this study we envisioned an antisense (chapter 
2) as well as a ribozyme (chapter 3) directed genetic approach to downregulate MTP mRNA 
levels. Both strategies are based on the specific recognition of the target mRNA by short 
complementary oligonucleotide sequences and can thus be valuable tools to investigate the effect 
of specific inhibition of VLDL production in mouse models and to explore the therapeutic 
potential of gene therapy directed against MTP. 
ZNF202 does affect a variety of genes involved in cellular transport of lipids and lipid 
metabolism in general 143. Especially its apparent linkage to HDL metabolism has drawn 
considerate interest. To address the perspectives of ZNF202 as therapeutic target in the correction 
of hyperlipidemia, we aimed to modulate hepatic ZNF202 expression via adenovirus (Ad) 
mediated gene transfer. First the murine ZNF202 gene was cloned from liver cDNA of C57BL/6J 
mice and Ad.CMV-ZNF202 was produced (chapter 4). To investigate the mechanism of 
ZNF202 repression deletion analysis of the mouse apoE promoter was performed. Via adenoviral 
mediated gene transfer we analyzed the effect of ZNF202 overexpression in a mouse hepatoma 
cell line on the expression of apolipoprotein gene clusters. Next the overall effect of ZNF202 in 
lipid metabolism was mapped in vivo in hyperlipidemic (LDLR-/-) and normolipidemic 
(C57Bl/6JICO) mice (chapter 5). The mice were injected intravenously with Ad.CMV.ZNF202 
resulting in significant hepatic overexpression of ZNF202. After several days, hepatic and serum 
lipid levels were analyzed together with hepatic mRNA levels of relevant lipid-related genes. 
Finally the results presented in this thesis will be discussed (chapter 6). 
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Abstract 
 
 In this study we describe the design and screening of antisense drugs against mouse 
Microsomal Triglyceride transfer Protein (muMTP) mRNA, which is a key enzyme in the 
assembly and secretion of atherogenic apolipoprotein B (apoB) containing lipoproteins in 
parenchymal liver cells. As the identification of suitable target sites accessible to antisense 
hybridization and the effectiveness of potent antisense drugs in a cellular context are rather 
unpredictable, we have pursued the an in vitro strategy.  Based on the predicted secondary 
structure of muMTP mRNA we designed 12 18-mer antisense oligodeoxynucleotides (AS-
ODNs). Evaluation of these AS-ODNs for their capacity to inhibit muMTP expression in a cell-
free transcription/translation assay revealed that 6 out of 12 antisense drugs (50%) led to more 
than 80% reduction of muMTP expression at which the most potent one (AS569) displayed an 
IC50 of 15 nM. Screening of AS569 for its ability to quench green fluorescent protein (GFP) 
derived fluorescence in GFP-muMTP transgenic COS-7 cells revealed a sequence specific and 
dose-dependent reduction of muMTP expression (IC50=50 nM). In conclusion, rational antisense 
drug design combined with a fast high throughput screening method was used to identify potent 
antisense drugs for muMTP. We anticipate that the most potent AS-ODN, AS569, is a promising 
lead in the development of potent antisense drugs for treating hyperlipidemia. 
 
Introduction  
 
 Antisense based gene inhibition continues to be an important approach in genomics-based 
research to study gene function and has led to the identification of novel drug targets. In fact, 
several antisense based therapies have been approved for clinical trials and are currently 
underway 1-3. Even though the use of antisense oligodeoxynucleotides (AS-ODNs) has helped 
considerably in the validation of gene function, the design of potent antisense drugs remains a 
challenge. A major obstacle is the ability of an antisense drug to engage in Watson-Crick 
hybridization with its target mRNA, which depends on the accessibility of the complementary 
target, and thus on its secondary and tertiary structure 4-6. Several strategies to identify accessible 
sites on the target mRNA have been pursued 7. Most straightforward is the screening of large 
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libraries of randomly selected antisense sequences targeted against various regions of the mRNA, 
albeit the success rate of this approach is less than 10% 8,9. To increase the success rate of 
antisense design a pre-selection step has been proposed, at which suitable target regions are 
defined on the basis of the secondary mRNA structure 10. Several computerized algorithms, such 
as Mfold, have been developed to predict the secondary structure of target mRNAs 11,12. 
After design of potential antisense drugs directed against the target mRNA a next barrier 
involves the rapid screening of the drugs for intrinsic antisense activity. The uptake and 
intracellular kinetics of AS-ODNs may be sequence dependent and this may considerably perturb 
the interpretation of the data. A cell-free assay to monitor AS-ODN activity will circumvent this 
setback 7. In particular assays for coupled transcription/translation, which cover antisense effects 
from transcription to translation show great potential in this regard 13.  As these assays are not 
necessarily reflective of the AS-ODN activity at a cellular level, it will be essential to reconfirm 
the in vitro data in a cellular context. We have previously described a sensitive and reproducible 
method to quantify AS-ODN efficacy that is not perturbed by differences in stability or cellular 
uptake 14. This method utilizes fusion constructs consisting of the target gene with the gene 
encoding enhanced green fluorescent protein (EGFP) as reporter and links the antisense activity 
directly to the decrease in EGFP expression. 
In this report we describe the rational design and screening of antisense drugs against 
mouse microsomal triglyceride transfer protein (muMTP), a rate limiting key enzyme in the 
synthesis of atherogenic apolipoprotein B100 (apoB100) containing lipoproteins 15-17 and 
promising target for intervention in hyperlipidemia 18-20. A two step strategy is pursued for the 
screening of antisense drugs involving a cell-free assay and a subsequent cellular fluorescence 
assay. From the predicted secondary structure of muMTP we have selected 9 regions that are not 
involved in Watson-Crick base-pairing and designed a set of 12 AS-ODNs targeting these 
epitopes. Using a cell-free combined transcription and translation assay those AS-ODNs were 
evaluated for their ability to specifically inhibit the expression of muMTP. The most effective 
AS-ODN was able to selectively inhibit the expression of muMTP at a cellular level.  
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Materials and Methods 
 
Materials 
Primers, phosphodiester and phosphothioate oligonucleotides (PS-ODN and PO-ODN), and Goldstar DNA 
polymerase were from Eurogentec (Seraing, Belgium). The pEGFP-C1 plasmid and the rabbit anti-EGFP Living 
Colors Peptide antibody were obtained from Clontech (Palo Alto, CA.). Vent® DNA Polymerase was from New 
England Biolabs (Beverly, MA). The TNT T7 coupled Reticulocyte Lysate System was from Promega (Leiden, The 
Netherlands). Exgen500 was obtained from Fermentas (St. Leon-Rot, Germany). Propidium iodide was purchased 
from Sigma (St. Louis, MO). Tetramethylrhodamine isothiocyanate 5,6-mixed isomers (TRITC) was from Molecular 
Probes (Eugene, OR). Cell culture agents were obtained from BioWhittaker (Verviers, Belgium). All other chemicals 
were of analytical grade. 
 
Table 1: Nucleotide sequences of the antisense drugs 
Name Sequence Target site* 
   
AS014 5’-GGATCATGCTGGCTCCCT 14-31 
AS176 5’-AGCCCACGCTGTCTTGCG 176-193 
AS344 5’-TCCCTATGATCTTAGGTG 344-361 
AS559 5’-TTTGTCTTGTTGGGCCTG 559-576 
AS569 5’-TTTTGACCACTTTGTCTT 569-586 
AS579 5’-AGAGCCTTAATTTTGACC 579-596 
AS1084 5’-CAGCTGAGGGAGCACTTC 1084-1101 
AS1414 5’-GTCTTCTTTCTTCTCTGG 1414-1431 
AS1767 5’-GGCATTTCAAAATGCAGG 1767-1784 
As1785 5’-CGGATCATTTTGCTTGCA 1785-1802 
AS1979 5’-GCTCTGTTCCTTTGATGT 1979-1996 
AS2791 5’-CATCTTAAATACAGGTAA 2791-2808 
   
SC569A 5’-TTTCTTCCATGATGTCTT  
SC560B 5’-TTTCCATGACTTCTTTGT  
* nucleotide numbers based on Gene Bank Accession nr. L47970 
 
Cloning of muMTP cDNA into pEGFP-C1  
Full-length cDNA coding for muMTP (cloned in pBLUEscriptII-KS; pMTP) was kindly provided by Dr L. Chan 
(Houston, USA). A 2.8 kb fragment (nt 25 to 2860, entailing the coding region and a part of the untranslated 3’ 
prime end) was PCR amplified from MuMTP using Vent DNA polymerase with extended primers containing Kpn-1 
and Bgl-II restriction sites (Forward: GGT.ACC.ATG.ATC.CTC.TTG.GCA.GTG; Reverse: 
AGA.TCT.CCT.GAA.TAG.GTT.CAA.CTT) and was subsequently cloned into the PME-1 site of pcDNA3.1 
(Clontech, Palo Alto, CA). The muMTP fragment was then excised by Kpn-I and Bgl-II digestion and the fragment 
ligated into Kpn-1/BamH1 digested pEGFP-CI plasmid to generate the C-terminal fusion construct pEGFP-muMTP. 
Sequencing of the plasmids confirmed the in-frame ligation of the muMTP cDNA. 
 
Cell-Free Assay for Coupled Transcription/Translation (TnT). 
TnT assays on T7 promoter containing pBluescriptII-muMTP were performed according to the manufacturer’s 
protocol with or without antisense ODNs (without the RNasin Ribonuclease inhibitor). After incubation for 60 min at 
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30°C protein sample buffer (62 mM Tris, 12.5 % glycerol, (v/v), 1.25 % SDS (w/v), 2.5% β-mercaptoethanol (v/v), 
and 0.25% bromophenol blue at pH 6.8) was added to the reaction mixtures, and the mixtures were denatured for 5 
min. at 95°C.  Samples were then loaded on 15% denaturing SDS-polyacrylamide gels, and the gels were run in 0.02 
M Tris, 0.16 M Glycine, and 0.1% SDS (w/v) at 100 V (30 min) and subsequently at 200 V (1 h). After fixation in a 
solution of 45% methanol (v/v) and 0.5 M acetic acid the gels were visualized and the synthesis of 35S-methionine 
labeled muMTP was quantified with a phosphor-imager (Molecular Dynamics, Sunnyvale, CA). 
 
Cell culture and transfection 
COS-7 cells (European Collection of Cell Cultures, Salisbury, UK) were seeded in 12-wells plates and grown at 37 
°C under a 5 % CO2 atmosphere in Dulbecco’s modified Eagle’s medium (DMEM) containing 10 % (v/v) fetal calf 
serum, 2 mM L-glutamine, 100 U ml-1 penicillin and 100 µg ml-1 streptomycin to a confluency of approximately 50 
%. Cotransfections of plasmid and phosphorothioate-modified ODN were performed with Exgen 500 (Fermentas) 
according to the manufacturer’s protocol. After 24 hours cells were detached from the culture plates with trypsin, 
centrifuged for 5 min at 400 g, washed once with 1 ml of phosphate buffered saline (PBS), and dispersed in 1 ml of 
PBS for flow cytometric analysis. 
 
Flow cytometry 
Immediately before FACS analysis, 3 µl of 1 µM propidium iodide was added. Cellular fluorescence of 
approximately 3,000 cells was determined in a Becton Dickinson FACS Calibur flow cytometer. Only single cells 
were gated in forward / sideward scatter plots; dead cells were excluded from the analysis by gating of propidium 
iodide-positive cells.  
 
Data processing - Data were analysed statistically for significance with two-tailed student t-test. GraphPad Prism 
Software (Graphpad Software Inc., San Diego, CA) was used for this purpose. 
 
Results 
 
Antisense Design 
 The first step towards the design of an effective muMTP mRNA reducing antisense drug 
involved the identification of domains within the muMTP mRNA that are not involved in base 
pairing reactions and that thus are open for hybridization with the antisense drug. To this end we 
have determined a single strand frequency plot for muMTP from the 25 energetically most 
favourable RNA configurations as calculated by the M-Fold algorithm 12. From this plot, 9 
domains throughout the muMTP mRNA could be identified with an increased single strand 
frequency (fig.1), and we designed 12 18-mer oligodeoxynucleotide sequences complementary to 
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Figure 1: Folding pattern of muMTP RNA. 
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4Plotted is the frequency of nucleotides within the 
muMTP mRNA to be involved in base-pairing or 
hairpin formation obtained from the 25 
energetically most favourable secondary 
structures as calculated via the Mfold algorithm. 
The numbered bars refer to the mRNA regions 
targeted by the antisense drugs. 
 
 
hese domains (table 1). Subsequently, we have screened the 18-mer AS-ODNs for their ability to 
nterdict muMTP synthesis in a rabbit retyculate lysate based system for coupled 
ranscription/translation, which is RNAseH competent (fig.2A). In the presence of muMTP 
DNA in vitro transcription/translation led to the formation of a [35S]methionine labeled 97 kD 
rotein which corresponded with full length muMTP. As a control, in vitro 
ranscription/translation was also tested for luciferase, by adding pLuc to the mixture. This gave 
n intense band of full length luciferase at 47 kD (data not shown). 
Formation of full length muMTP was significantly quenched (>65%) in the presence of 
nly 150 nM of AS-ODNs, targeting domains 344, 575, 579, 1084, 1414, and 1767  (fig. 2B). In 
articular antisense drugs targeting site 569 and 1414 appeared to be very effective with >95% 
nhibition (p<0.001). To verify that this inhibition was not caused by a sequence-dependent 
rtifact, also AS-ODNs which target sites flanking the AS569 stretch were tested for their 
 
35Figure 2: Effect of antisense drugs on [ S]Met-
muMTP formation in a reticulocyte lysate system 
for coupled transcription/translation. Rabbit 
reticulocyte lysate was incubated for 60 min at 30°C 
with RNA-T7 polymerase, methionine deficient amino 
acid mix, [35S]Methionine, and pMTP (200 ng) in the 
absence (control) or presence of phosphodiester ODN 
(150 nM). The mixture was applied to SDS-PAGE gel-
electrophoresis and analyzed on the PhosphoImager for 
the intensity of the muMTP (A). The intensity of the 97 
kD MTP protein bands were quantified and the control 
was set at 100% (B). Values are means ± SD of three 
independent experiments. 
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muMTP translation inhibitory potency. As these AS559 and AS579 were equally effective 
inhibitors but structurally different, we can assume that the inhibition is achieved through domain 
specific interaction. 
 
 
Figure 3 Dosis-effect study of the most potent 
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 antisense drugs. Rabbit reticulocyte lysate was 
incubated for 60 min at 30°C with RNA-T7 
polymerase, methionine-deficient amino acid mix, 
[35S]Methionine, and pMTP (200 ng) in the presence of 
an increasing concentration of antisense drugs (0-150 
nM). The mixture was applied to SDS-PAGE gel-
electrophosesis and analyzed on the PhosphoImager for 
the intensity of the muMTP protein bands (A). 
Intensities of the 97 kD bands were calculated by image 
analysis and IC50 values were calculated from 
sigmoidal concentration effect curves using Graphpad 
Prism Software (B). Values are means ± SD of three 
independent experiments. 
 
In vitro dose effect studies confirmed that the AS-ODNs AS559/579 and AS1412 were 
lready able to reduce muMTP formation at nanomolar concentrations (fig.3). IC50 values 
alculated from the dose-effect studies ranged from 38 nM for AS1412 to only 15 nM for AS569. 
he inhibitory activity of AS569 was sequence specific as [35S]-muMTP synthesis was not 
ffected by the presence of two scrambled ODN sequences, while only AS569 gave a significant 
80% reduction (P<0.001), indicating that the inhibitory effect of AS569 can be attributed to a 
ntisense specific mechanism (fig.4). 
 
Figure 4: Specificity of AS569 on [35S]Met-
muMTP formation in a reticulocyte lysate 
system for coupled transcription/translation. 
Rabbit reticulocyte lysate was incubated for 60 
min at 30°C with RNA-T7 polymerase, 
methionine deficient amino acid mix, 
[35S]Methionine, and pMTP (200 ng) in the 
presence of phosphodiester ODNs (100 nM). 
The mixture was applied to SDS-PAGE gel-
electrophosesis and analyzed on the 
PhosphoImager for the intensity of the muMTP. 
The intensity of the 97 kD MTP protein bands 
were quantified and the control was set at 
100%.Values are means ±SD (n=3) and ** 
indicates p<0.001. 
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Activity of the antisense drugs in a cellular context. 
To establish antisense activity of AS569 in a cellular setting, we have set-up a flow 
cytometry based read-out system for muMTP. C-terminal fusion constructs of muMTP with 
EGFP (pEGFP-muMTP) were made by ligating PCR-amplified cDNA, encoding muMTP, into 
the multiple-cloning site of the pEGFP-C1 fusion vector. Sequence analysis confirmed a correct 
in-frame ligation of the cDNA and the absence of any sequence errors in the inserts. By flow 
cytometric analysis, it was shown that transfection of COS-7 cells with pEGFP and pEGFP-
muMTP proceeded at equal efficiency, albeit that the average fluorescence intensity of EGFP-
muMTP transfected cells was lower than that of EGFP itself (data not shown). This indicated that 
the EGFP moiety of the fusion protein retained its activity. Fluorescent microscopy revealed that 
EGFP and the EGFP-muMTP fusion proteins were both localized in the cytosol. 
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 Specificity of antisense activity of AS569 in a EGFP-muMTP fusion protein-based cellular read-out. 
ells were transfected with 2 µg of pEGFP (●) or pEGFP-muMTP (○), together with the indicated 
tions of phosphodiester AS569 using Exgen500 (charge ratio 1:3). After 24 hrs cells were analyzed for 
ession by flow cytometry. Percentage of GFP positive cells transfected with plasmid but without AS-ODN 
t 100% (A). Under similar conditions COS-7 cells expressing either EGFP or EGFP-muMTP (white bars) 
sfected with 50nM of AS569 (black bars) or scrambled ODN (Sc569; grey bars) (B) Values are means ± 
. 
ext, we have optimized the transfection conditions for COS-7 cells. Fluorescent 
opy showed that while EGFP-muMTP was localized mainly in cytosolic vesicles 
mes) as well as in the nucleus in 30-40% of cells, the TRITC labeled PS-ODN was 
inantly found in the latter organelle (data not shown). To determine the potency and 
ity of AS569 to inhibit the expression of muMTP RNA we transfected COS-7 cells with 
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different concentrations of TRITC labeled AS569 in the presence of either pEGFP-muMTP or 
pEGFP (fig. 5A). Our results show that AS569 is also a potent inhibitor of EGFP-muMTP at a 
cellular level and that the antisense effect is concentration-dependent (IC50 = 54 nM). However, 
at high concentrations (> 0.05 µM) the oligonucleotide also affected the expression of EGFP, 
although to a lesser extent (p<0.05). The sequence specificity of EGFP-muMTP inhibition by 
AS569 at low concentration was further corroborated by the lack of effect of scrambled ODN (50 
nM) on the expression of EGFP-muMTP (fig. 5B). The expression of EGFP in COS-7 cells 
transfected with our control pEGFP also remained unaffected by Sc569. 
 
Discussion 
  
This study describes the rational design and characterisation of antisense drugs that target 
the gene encoding murine MTP, which catalyzes a rate-limiting step in the assembly of pro-
atherogenic apoB100 containing lipoproteins, i.e. VLDL and LDL 15-17. From secondary mRNA 
structure analysis for muMTP mRNA using the Zuker algorithm (Mfold version 3.0) we have 
selected domains within the muMTP mRNA, which are not involved in base-pairing reactions 
(hairpin or pseudoknot formation) and thus are accessible to antisense drug hybridisation 11. 
Antisense drugs targeting these domains were tested for their ability to down-regulate muMTP 
mRNA levels in a two step-strategy involving rapid prescreening under cell free conditions and 
subsequent verification of potentially active antisense drugs in a cellular read-out system.  
 For the former we have used a T7 RNA polymerase promoter coupled reticulocyte lysate 
system. We found that 6 out of 12 (50%) of the designed antisense drugs resulted in >80% 
inhibition of MTP expression. Although the reliability of computer predictions for folded RNA 
structures is debatable 21,22, the success rate of identification of effective antisense sequences in 
this study is considerably higher than the 2-10% normally reported for unbiased antisense design 
8,9. For further characterization we selected the most potent antisense sequences that resulted in 
almost complete inhibition of MTP expression: AS559/AS579 and AS1414. Dose-effect studies 
showed that each of these 4 antisense drugs displayed IC50 values in the nanomolar range (47 to 
15 nM). In particular nucleotide strand 559-599 appeared to be sensitive to antisense drug 
hybridization. Antisense specificity of AS569 was confirmed by the lack of effect of a scrambled 
ODN. 
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 In the second step the most potent antisense drugs were evaluated for their antisense 
effects in a cellular assay. For this purpose we used the phosphorothioate-modified AS569, since 
PS-ODNs are less sensitive to nucleolytic degradation 23. In a previous report we have described 
a novel cellular screening assay for the selection of effective AS-ODNs with a sequence-specific 
mode of action 14. In analogy to this study, we have used COS-7 cells transfected with 
muMTP/EGFP fusion protein to directly correlate antisense activity with EGFP-derived 
fluorescence by flow cytometry. This sensitive assay appeared to be quantitative and obviated the 
need of specific antibodies or isoform-specific activity assays. The high reproducibility of this 
assay is probably due to elimination of variable transfection efficiencies as complicating factor in 
the assessment of antisense effectiveness. We had already shown in a previous study that after 
cotransfection of plasmid and fluorescently labeled ODNs 14, all EGFP-positive cells had taken 
up ODNs and fluorescence microscopy showed that AS-ODNs are predominantly present in the 
nucleus. Therefore, in this assay antisense effects will not be masked by a low transfection. 
In our cellular assay AS569 displayed an IC50 value of 54 nM, which is comparable to 
IC50 values of other potent PS-ODNs tested in a cellular environment 9,24. True antisense effect 
by AS569 was found to be concentration dependent. At higher concentrations of AS569 also non-
target specific effects could be detected as judged by the reduced EGFP expression, although to a 
lesser extend with 77% reduction of EGFP expression compared to almost 95% reduction of 
EGFP-muEGFP expression at the highest AS569 concentration. Nonspecific antisense effects at 
high concentrations by more nuclease tolerant PS-ODNs have been reported earlier 25,26. It is 
believed that PS-ODNs may engage in sequence-dependent and -independent interactions, largely 
of electrostatic and induced dipole nature, with cellular proteins  27,28. In particular key regulatory 
proteins such as transcription factors are notorious PS-ODN binders 29. With the recent advance 
in antisense drug design (such as the development of peptide nucleic acids, PNAs) the efficacy of 
antisense drugs has been improved and unfavorable side effects attenuated 2,30,31. Specific 
delivery to tissue by conjugating ODNs to ligands of targeted receptors or liposome mediated 
targeting of ODNs may further improve the effectiveness of the antisense drugs 32,33. Indeed we 
have observed a marked inhibition of muMTP in parenchymal liver cells by targeting 
glycoconjugated PNA569 (which targets the same mRNA region as AS569) against the 
asialoglycoprotein receptor 34. 
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In conclusion, the use of rational antisense drug design combined with a two step 
evaluation strategy involving a cell free assay and a subsequent cellular read-out assay based on 
an EGFP fusion construct appears to a be very effective strategy in the design of potent antisense 
drugs. A specific AS-ODN targeted against muMTP was obtained and shows therapeutic 
potential in treatment of hyperlipidemia. Moreover, we identified a potential region within the 
muMTP mRNA that is accessible to other antisense and RNA interference based therapies.  
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Abstract 
 
 Therapeutic reduction of very low-density lipoprotein (VLDL) levels by intervention in 
its biosynthesis in the liver is considered a very legitimate approach to lower the risk of 
cardiovascular diseases (CVD). Microsomal triglyceride transfer protein (MTP), catalyzes a rate 
limiting step in the assembly of VLDL and thus, constitutes an attractive target for VLDL 
lowering. In this study we present a new gene therapeutic strategy to stably reduce MTP levels 
involving the use of ribozyme vectors. Three hammerhead ribozymes were designed against 
mouse MTP, targeting regions within the MTP mRNA that appeared accessible for ribozyme 
hybridisation from RNA folding analysis and that encompassed a GU↓X cleavage site: Rz342, 
Rz581 and Rz1802. The intrinsic activity of the ribozymes was assessed under cell free 
conditions after incubation of [32P]-labeled MTP RNA (0.5 µM) with in vitro transcribed 
ribozymes (2.0 µM). For all ribozymes, endonuclease activity was demonstrated and the size of 
the cleavage products concurred with their predicted fragment length. Kinetic analysis gave Vmax 
values ranging from 12 to 140 nM/ minute at a Km of approximately 7 µM, at which the tandem 
repeat RzT581 appeared to be most potent. Adenoviral expression vectors were generated for 
Rz581 and RzT581 under control of different polymerase-II and III dependent promoters (i.e. 
CMV and tRNA or U6+27, respectively). MTP cDNA transfected Hela and mouse hepatoma 
mAT3F2 cells were transduced with the adenoviral ribozymes. Ribozyme based reduction of 
MTP mRNA levels was observed in both cell lines but depended on the type of expression 
cassette used. In conclusion, ribozyme vectors were generated that affect a significant 
downregulation of MTP expression in vitro. The most potent ribozyme vector could not only be a 
powerful mechanistic tool for future studies on hepatic MTP, but could form a starting point for 
the development of a novel targeted therapy for reducing MTP activity and thus levels of the 
atherogenic VLDL. 
 
Introduction 
 
 Elevated levels of apolipoprotein B100 (apoB100), the structural protein of circulating 
lipoproteins carrying triglycerides and cholesterol 1, are a risk factor for cardiovascular diseases. 
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A key enzyme in the assembly and secretion of apoB containing lipoproteins is microsomal 
triglyceride transfer protein (MTP)2,3. This makes MTP a potential target in search of therapeutic 
agents that are able to reduce VLDL and LDL. Several synthetic MTP inhibitors have already 
been described, but their action is not limited to the liver and may cause adverse effects including 
deficiency of lipid soluble vitamins 4-6. A straightforward strategy to reduce MTP is to intervene 
in its biosynthesis, which could amongst others be effected by hammerhead ribozyme therapy. 
Ribozymes are small RNA sequences with endonuclease activity 7-9 and can be rendered 
substrate specific by flanking the catalytic domain with short sequences complementary to the 
target RNA. However, the successful application of ribozymes depends on the target site 
accessibility, efficient delivery, and stability. 
In search for suitable sites, the RNA cleavage site not only needs to be accessible but 
should also contain a specific triplet sequence. The specificity to ribozyme hybridization is 
determined by the secondary RNA structure and possible association with cellular proteins and is 
difficult to predict. Various algorithms have been developed to calculate secondary structures of 
RNA such as Mfold which can be helpful but have proven not to be fully reliable 10,11. Secondly, 
the preferred triplet for cleavage was suggested to be 5’-GU↓X where X is either C, A or U, as 
most of the naturally occurring ribozymes targeted this triplet 12-14.  
There are two ways to introduce ribozymes to target cells. Ribozymes can be delivered to 
the aimed target exogenously as chemically synthesized oligodeoxynucleotides potentially 
equiped with phosphothioate or inverted nucleotide groups to confer stability, or they can be 
synthesized endogenously upon transfer of ribozyme expression vectors to the target cells 15. For 
the latter strategy the efficacy of ribozyme vectors will depend on the expression level and 
intracellular distribution which are governed by the choice between RNA-polymerase III (pol III) 
dependent promoters (such as the U6 snRNA and tRNA promoter) which generally are fit for 
driving transcription of small RNAs, and RNA-polymerase II (pol II) dependent viral promoters 
(like CMV) 16,17. Furthermore, the enzymatic stability of the ribozymes and proper folding of the 
catalytic domain can be improved by introducing flanking sequences and/or hairpins. 
Illustratively, introduction of artificial stem-loops was reported to considerably enhance the 
stability of hammerhead ribozymes and to promote a catalytically active configuration 18,19.  
In this study we describe the development of a mouse MTP (muMTP) specific 
hammerhead ribozymes for ribozyme based gene therapy to lower VLDL production by the liver. 
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Three target sites were selected and ribozymes designed targeting these sites, which proved to 
display targeted endonuclease activity in a cell free assay system. To facilitate ribozyme transfer 
to liver cells we have, for the most potent ribozyme sequence generated a panel of adenoviral 
vectors, at which ribozyme expression was under control of various promoters. Finally we have 
demonstrated that adenoviral delivery of one of these adenoviral ribozymes resulted in a 
reduction of muMTP expression at a cellular level. 
 
Materials and Methods 
 
Cell Culture 
Mouse hepatoma cell line mhAT3F2 20 were cultured in Dulbecco’s Modified Eagle’s Medium with F-12 (cat. no. 
31331, Gibco) supplemented with 10% fetal calf serum (Gibco), 100 IU/ml Penicillin, 100 µg/ml Streptomycin, 20 
mM GlutaMAX I , 400 nM Insulin (Sigma), 10 nM Dexamethasone (Sigma). Hela, Per.C6 and 911 cells 21,22 were all 
cultured in Dulbecco’s Modified Eagle’s Medium (cat. no. 41966, Gibco), supplemented with 10% fetal calf serum 
(Gibco), 100 IU/ml Penicillin, 100 µg/ml Streptomycin, 2 mM GlutaMAX I (Gibco), at which for Per.C6 cells 10 
mM MgCl2 was added to the medium. For large scale production of recombinant adenovirus in Per.C6 cells fetal calf 
serum (10%) was substituted with 2% horse serum (Gibco).  
 
Table 1. Ribozyme constructs 
 
R
T
w
o
5 
ibozyme and Target constructs 
hree ribozymes were designed that targeted regions in the muMTP mRNA containing a GUX triplet and in addition 
ere predicted by Mfold 23 to be single stranded (Table 1). The sense and antisense strands of synthetic 
ligonucleotides (Eurogentec, Seraing, Belgium) encoding the ribozymes were annealed and cloned into the SmaI 
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site of pBluescript II KS (Stratagene). Orientation of the insert was determined by restriction analysis and the 
constructs were sequence verified (LGTC, Leiden, The Netherlands). Constructs with reverse orientation of the 
ribozymes were used as negative control. To obtain RNA substrates for the in vitro ribozyme cleavage reactions, two 
PCR fragments of muMTP were generated using the following two primer pairs: MTP1 forward 
5’CAGAGGGAGCCAGCATGATC and MTP1 reverse 5’ TCCTGCTATGGTTTGTTGGA and MTP2 forward 
5’AGAGATACGATGTCTCCTTC and MTP2 reverse  5’AGAATAAGCCCTTTCACCAC. The MTP1 amplicon 
spanned nucleotides 12 to 768 (nucleotide numbers are based on GeneBankl accession number L47970) and 
contained the target site for Rz342 and Rz581, while that of MTP2, spanning nt 1550 to 2219, contained the target 
site for Rz1802. Both PCR products were cloned into pGEM-T (Promega) and verified by sequencing. 
 
Construction of Adenoviral Vectors 
The construction of pTZU6+27 and pTZ18U containing respectively the U6+27 and the tRNAmet expression cassette 
was described by Good et al 19. Rz581 was excised from the pBluescript backbone as a SalI-XbaI fragment.  The 
shuttle vector pAdTrack-cmvRz581 was generated by inserting the Rz581 fragment in a SalI and XbaI digested 
pAdTrackCMV. To obtain the shuttle vectors pAdTrack-U6.Rz581 and pAdTrack-tRNA.Rz581, Rz581 was first 
inserted into the SalI and XbaI sites of respectively the U6+27 and the tRNAmet expression cassette. The expression 
cassettes were then cut out with KpnI and HindIII and cloned into pAdTrack. RzT581 was cloned into 
pAdTrackCMV via restriction sites NotI and HindIII. Recombinant adenoviral plasmids was generated by 
homologous recombination with pAdEasy1 in BJ5183 cells as described previously 24. Correct clones were 
propagated in STBL2 cells (Life Technologies). For the production of adenoviral ribozymes Per.C6 cells were 
transfected with 3 µg Pac-I-linearized adenoviral construct on 35 mm dishes using LipofectAMINE PLUS kit as 
described by the manufacturer (Life Technologies). After 16 hours transfection medium was replaced by growth 
medium. Transfected cells were harvested at day 7 post-transfection and after three cycles of freeze-thaw the lysate 
was used for large-scale production of adenoviral ribozymes in Per.C6 cells. Virus was purified by CsCl 
centrifugation steps and dialysis. Final yields were assessed via a plaque assay on 911 cells. 
 
In Vitro Transcription and Ribozyme Cleavage Reaction 
For in vitro transcription the T7 promoter based RiboMAX system was used according to the manufacturer’s 
protocol (Promega, Leiden, the Netherlands). Ribozyme constructs in pBluescript II KS and target sequences in 
pGEM-T were linearized with EcoRI and NotI, respectively. Target RNA sequences and ribozymes were 
radiolabeled  by the incorporation of  [32Pα]UTP (Amersham Biosciences, Buckinghamshire, England) during in vitro 
transcription. After the in vitro transcription reaction, the reaction mixture was treated with RQ1 RNase-free DNase 
(Promega) and the unincorporated nucleotides were removed by isopropanol precipitation. RNA concentrations were 
determined by measuring optical density at 260 nm. For the cleavage reaction substrate (10 pmol) substrate and 
ribozyme RNA (40 pmol) were mixed in 18 µl of Tris buffer (50 mM; pH 7.5). The mixture was heated at 85°C for 2 
min followed by a 10 min incubation at 37ºC. MgCl2 (20 mM) was added to a final volume of 20 µl and the mixture 
was incubated for up to 60 min at 37ºC. The reaction was stopped by the addition of an equal volume of loading 
buffer (90% formamide, 20 mM EDTA, 0.03% bromophenol blue, 0.03% xylene cyanol). This mixture was heated at 
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95ºC for 2 min and the samples were run on a 6% polyacrylamide-8 M urea gel in Tris-borate EDTA buffer. 
Cleavage products were visualized and quantified with a phosphorimager (Molecular Dynamics, Sunnyvale, CA). To 
determine the cleavage kinetics of the four ribozymes, 0.1 uM of ribozyme was incubated different concentrations of 
substrate (0.25, 0.5, 1, 1.5 uM) and the reaction was monitored over a period of 10 min. Reaction velocities were 
determined and Km and Vmax were calculated by non-linear regression analysis 
(V=(Vmax×[substrate])/(Km+[substrate]). 
 
Transfection and Infection 
Hela cells were seeded in a 12-wells plate and grown to a confluency of 50%. Cells were transfected with pEGFP-
muMTP by lipofection (FUGENE). At 24 hours post-transfection cells were infected with either AdGFP-Rz581, 
AdGFP-RzT581, AdGFP-U6.Rz581, AdGFP-tRNA.Rz581, or control AdGFP (MOI=100). Cells were harvested and 
lysed with Trizol 48 hours after transfection. To address ribozyme effects on endogenous muMTP expression, 
mhAT3F2 cells were seeded in a 12-wells plate and grown to a confluency of 60-70% before infection. Infection 
with recombinant adenoviruses and harvesting of the cells was performed under similar conditions as described for 
Hela cells. 
 
Quantitative Real Time PCR analysis 
Total RNA from Hela and AT3F2 infected cells was isolated with Trizol according to the manufacturer’s protocol 
(Eurogentec SA, Seraing, Belguim). Purified RNA was treated with RQ1 RNase-free DNase (Promega, 1 units/ 2 µg 
of total RNA) and reverse transcribed with SuperScript II Reverse Transcriptase (Invitrogen) according to the 
protocols supplied by the manufacturers. Quantitative gene expression analysis was performed on an ABI prism7700 
Sequence Detection System (Applied Biosystems, Foster City, CA) using SYBR Green technology as described 
earlier 25. For design of the PCR primers (table 2) Primer Express 1.7 software was used with the manufacturer's 
default settings (Applied Biosystems) and primer sets were validated for amplification efficiency. The absence of 
genomic DNA contamination in the RNA preparations was confirmed by using total RNA samples that had not been 
subjected to reverse transcription. Hypoxanthine-guanine phosphoribosyl transferase (HPRT) and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) were used as the standard housekeeping genes. 
 
Data Analysis—The significance of differences in relative gene expression numbers Ct (Ct(HPRT)–Ct(target gene))  
measured by real time quantitative PCR was calculated using a two-tailed Student's t test. Probability values less than 
0.05 were considered significant. 
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Table 2. PCR Primers 
G
hu
h
m
m
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Des
 
an 
hyb
prep
 ene GenBank 
Acces. 
Forward Primer Reverse Primer 
GAPDH BC029618 CAGAACATCATCCCTGCCTCTA CCAGTGAGCTTCCCGTTCA 
uHPRT NM_000194 TGACACTGGCAAAACAATGCA AGCTTGCGACCTTGACCATCT 
uHPRT J00423 TTGCTCGAGATGTCATGAAGGA AGCAGGTCAGCAAAGAACTTATAG 
uMTP L47970 TCAAGAGAGGCTTGGCTAGCTT GGCCTGGTAGGTCACTTTACAATC  
sults 
 
Figure 1. Identification of 
potential target sites for 
hammerhead ribozymes 
against muMTP. Accessibility 
for ribozymes was determined 
by mapping of the secondary 
structure of muMTP mRNA 
using Mfold algorithm. Based 
on the single strand frequency 
and the presence of a cleavable 
triplet according to the GUX-
rule three target sites were 
identified for ribozyme(A). The 
general architecture of of a 
ribozyme, at which the 
catalytic domain of the 
ribozyme, stem II, is flanked by 
two hybridizing arms that form 
stem I and III, respectively (B). 
 
 
 
 
 
 
 
 
ign of Ribozymes targeted against muMTP 
In a previous study we have identified several domains throughout the muMTP RNA with 
increased average single strand frequency that appeared to be accessible for antisense 
ridization and thus capable of inhibiting muMTP expression (Vrins et al. manuscript in 
aration). Three of these domains contained a GUX triplet and were selected as potential 
53
Chapter 3 
ribozyme target sites (fig. 1A). A schematic diagram of the secondary structure of one the three 
hammerhead ribozymes is shown in figure 1B. The catalytic domain (stem II) is flanked by 8-9 
nucleotide long hybridizing arms complementary to muMTP mRNA (stem I and III). The 
ribozymes Rz342, Rz581, and Rz1802 are defined by their respective target site of hydrolysis.  
 
Figure 2. Cleavage of muMTP RNA by 
32
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5ribozymes in cell free assay system. [ P]UTP-
labeled muMTP RNA (10 pmol) was incubated 
with the RNA ribozyme (40 pmol) for 60 minutes 
at 37 ºC. Control experiments were carried out 
using antisense ribozyme sequences of R342, 
Rz581, or Rz1802. Reaction mixtures were 
applied to 6% polyacrylamide urea gel 
elecrophoresis and gels analyzed by 
autoradiography. The sizes of the RNA fragments 
are indicated on the left. 
 
 
 
 
 
ell free testing of ribozyme activity 
To test the ability of the ribozymes to cleave their target, constructs encoding the 
ibozyme and the ribozyme target sequences were cloned into a T7 promoter containing vector 
Bluescript. Each ribozyme was able to cleave its substrate and to produce two fragments (fig. 2, 
ane 2, 5, 8) with the predicted fragment size. Control transcripts from the minus strand of the 
ibozyme constructs did not show any activity (lane 3, 6, 9). The catalytic activity of all three 
ibozymes was Mg2+ dependent (data not shown). To assess the intrinsic activity of the ribozymes 
e monitored product formation in time (fig. 3). In the process of cloning the Rz581 construct in 
Bluescript we obtained a clone containing Rz581 in tandem formation (RzT581). This tandem 
ibozyme construct encoded an active ribozyme (data not shown), at which the 3’ Rz581 had a able 3. Kinetics of ribozyme mediated target RNA cleavage  
 Km (µM) Vmax (nmolar/min) 
   
Rz342 8 12.5 
Rz581 5 14.2 
Rz1802 7.5 12.5 
RzT581 5.7 187.4 4 
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single nucleotide deletion within the stem-I hybridizing arm. Although Rz581 and RzT581 share 
the same target site the latter proved to be considerably more active (Fig. 3A). Moreover as 
shown in figure 3B, RzT581 was also found to be more efficient than Rz342 and Rz1802. Next, 
we analyzed the cleavage kinetics of the four ribozymes under substrate excess conditions. For 
each ribozyme the cleavage reactions with different substrate concentrations was followed over a 
time period of 10 minutes. As shown in table 3, all four ribozymes have similar Km-values. While 
the maximum cleavage rates (Vmax) of Rz581, Rz342, and Rz1802 were identical, that of 
RzT581 was found to be more than 10-fold higher compared to the other ribozymes. 
 
Figure 3.  Time curves of ribozyme 
mediated cleavage reactions in cell 
free system. [32P]UTP-labeled 
muMTP RNA (10 pmol) was 
incubated with the ribozymes RNA 
(40 pmol) at 37 ºC and samples were 
taken at several time points. Reaction 
mixtures were applied to 6% 
polyacrylamide urea gel elecrophoresis 
and subjected to autoradiography (A). 
The intensity of the cleavage products 
(3’ and 5’ products) was analyzed on 
the phosphoImager. Product formation 
is plotted vs time for Rz342 (▲), 
Rz581 (■), Rz1802 (○), and 
RzT581 (●) (B). 
 
 
 
 
 
 
 
 
 
Effect of Adenovirus-mediated Rz581 expression on muMTP RNA levels in Hela cells 
 To evaluate the mRNA cleaving capacity of the muMTP ribozymes at a cellular level we 
have generated recombinant adenoviral vectors. Although all muMTP targeting hammerhead 
ribozymes demonstrated efficient endonuclease activity, Rz581 appeared to be the most 
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5able 4. Effect of adenoviral ribozyme transfer to EGFP-muMTP transfected Hela cells on the relative 
GFP-muMTP expression  
 EGFP-muMTP 
relative to HPRT 
EGFP-muMTP 
relative to GAPDH 
GAPDH relative to 
HPRT 
Ad-GFP 100.0 100.0 100.0 
AdGFP-CMV.Rz581 165.3 170.5 96.6 
AdGFP-CMV.RzT581 55.9* 55.9* 104.1 
AdGFP-U6.Rz581 64.3* 58.7* 100.0 
AdGFP-tRNA.Rz581 52.4* 65.4* 83.5 
 p<0.05 
ote: No muMTP RNA levels detected in untransfected cells (Ct-values 38.4 compared to 19) romising under cell free conditions. Therefore we choose this target construct to generate a 
eries of recombinant adenoviral vectors. In earlier in vitro studies it was already suggested that 
ranscript stability, expression level and transcript location critically depends on the promotor 
sed to drive ribozyme transcription 16-19, and this seemed to be corroborated by our finding that 
zT581 was more active than Rz581 itself. Therefore we have in this study generated different 
denoviral vectors at which ribozyme expression was under the control of the CMV, the U6+27 
r the tRNAmet promoter, respectively, termed AdGFP-CMV.Rz581, AdGFP-U6.Rz581, and 
dGFP-tRNA.581. With RzT581 being the most potent ribozyme against muMTP mRNA, we 
lso generated recombinant adenovirus AdGFP-CMV.RzT581. MuMTP deficient Hela cells were 
ransfected with pEGFP-muMTP carrying the muMTP gene. After pre-transfection, Hela cells 
ere infected with one of the adenoviral ribozymes or with control AdGFP. MuMTP mRNA 
evels were analyzed by quantitative real time PCR at which the amplicon produced by the MTP 
rimers encompassed the putative ribozyme target site GUC581 (table 4).  Except from AdGFP-
MV.Rz581, all adenoviral based ribozymes expressions led to a significant 40% reduction of 
uMTP expression.  
ffect of adenoviral ribozymes on endogenous muMTP expression in vitro 
Next, we have examined to what extent adenoviral ribozyme activity is influenced by the 
xpression cassette in vitro. The various ribozyme vectors were tested for their ability to inhibit 
ndogenous muMTP expression in the mouse hepatoma cell line mhAT3F2. MhAT3F2 cells 
ere transduced at almost 100% efficiency as jugded from the percentage of GFP positive cells at 
6 
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24 hours post-infection. Relative muMTP mRNA levels were analyzed 24 hours after infection 
and compared with those of mock infected controls (fig. 4). Both CMV driven ribozyme vectors, 
AdGFP-CMV.Rz581 and AdGFP-CMV.RzT581, inhibited muMTP expression, albeit that the 
reduction did not reach significance. AdGFP-U6.Rz581 had no apparent effect on muMTP 
expression either. In contrast, infection with AdGFP-tRNA.Rz581 resulted in a significant 
reduction of muMTP mRNA levels (55%, p<0.05). 
 
Figure 4. Effect of adenoviral ribozyme transfer to mhAT3F2 
hepatoma cells on endogeneous muMTP expression (± SEM). Mouse 
hepatoma AT3/F2 cells were seeded in a 12-wells plate and grown to a 
confluency of 60-70% before infection. Cells were infected with AdGFP, 
AdGFP-CMV.Rz, AdGFP-CMV.RzT581, AdGFP-U6.Rz581, or AdGFP-
tRNA.Rz581 (MOI=100) and 24 hours post-infection cells harvested for 
RNA isolation. The muMTP mRNA levels were assessed and normalized 
to HPRT levels using quantitative real time PCR analysis. Values are 
means ± S.D. of a quadruplicate determination (P<0.05 is indicated by an 
asterix). 
 
 
 
 
 
 
 
Discussion 
 
 On the basis of RNA folding analysis for antisense drug development (Vrins et al. 
manuscript in preparation) we have defined three GU↓X candidate sites (GUA342, GUC581, and 
GUC1802) for ribozyme design. A cell free screening assay revealed that all ribozymes were able 
to cleave muMTP RNA, at which the cleavage products possessed the expected product lengths 
indicating that the ribozymes hydrolyzed their RNA substrates specifically at the aimed cleavage 
site. A tandem Rz581 repeat (RzT581) bearing a single nucleotide deletion at the stem I 
hybridizing arm of the 3’ ribozyme unit, which incidentally was generated during ribozyme 
cloning, proved to be approximately 10-fold more efficient in cleaving its substrate than its single 
ribozyme counterpart and the other ribozymes. Although it cannot be excluded that RzT581 
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contains two fully functioning muMTP cleaving domains 27, the mutation in the 3’ ribozyme is 
likely to attenuate hybridization with its target RNA. In view of the unexpectedly high (10-fold) 
increase in Vmax, it is however more probable that the extra stem loop favors a catalytically active 
configuration of the ribozyme. Moreover, flanking hairpins will also provide further protection 
against exonucleases thus increasing its half life 28.  
The high efficacy of RzT581 underscores the importance of ribozyme stability and 
conformation which both dictate ribozyme levels that can be achieved intracellularly. To improve 
the stability and expression level of Rz581 we generated a series of adenoviral vectors based on 
Rz581, at which the promoter and flanking sequences was varied. Expression of adenoviral 
ribozymes is often driven by a pol II dependent promoter of viral origin, eg. CMV and RSV 29-32, 
generating 5’ capped and polyadenylated transcripts. By contrast, pol-III dependent promoters, 
such as U6snRNA or tRNAmet,  are eminently equipped for mediating high expression of small 
RNA transcripts in eukaryotic cells 19. Moreover, U6snRNA and tRNAmet derived transcripts will 
be provided with stabilizing 3’ stem loops. For comparison we have also generated a CMV 
driven adenovirus for the tandem repeat ribozyme RzT581 (Ad-CMV.RzT581), arguing that the 
CMV expression cassette would benefit most from the higher stability of the tandem ribozyme. 
Except for the CMV.Rz581 adenovirus, all of the GUC581 targeted ribozyme vectors were 
demonstrated to be effective in vitro in GFP-muMTP expressing Hela cells. Both RzT581 and the 
Rz581 transcripts expressed from the RNA-polymerase III driven cassettes effected a significant 
reduction of GFP-muMTP expression, supporting our initial notion that indeed the addition of 
stabilizing sequences including artificial stem loops or an extra ribozyme sequence is a key factor 
in increasing ribozyme efficacy.  
Surprisingly, only AdGFP-tRNA.Rz581 was able to significantly lower endogenous 
muMTP mRNA levels in mhAT3F2 cells. CMV driven expression of ribozymes tended to reduce 
muMTP expression albeit not significant, while the U6 transcript appeared to be completely 
ineffective. The observed differential effect may be attributable to differences in the folding of 
endogenous versus cDNA construct derived muMTP transcripts. Alternatively, promoter- or cell-
dependent differences in ribozyme expression, stability or intracellular location may underlie the 
observed effects 18.  In regard to the latter it is important to note that eukaryotic pol II driven 
transcripts, being guanosine capped and polyadenylated,  are generally exported to the cytoplasm, 
while U6+27 and tRNA derived transcripts remain primarily located in the nucleus 18,19. 
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Although this explain the inability of U6+27 generated ribozymes to quench muMTP expression 
in mhAT3F2 cells, it leaves unanswered the high activity of the tRNAmet-promoter based 
construct. Conceivably, the high intracellular levels of tRNA driven Rz581 may compensate for 
the suboptimal location of the transcript. In that case, the use of a conventional  tRNA 
promoter/terminator, favoring cytosolic translocalisation of derived transcripts, could further 
improve the inhibitory potential of the ribozyme 33,34.  
Although a number of MTP-inhibitors already were shown to have therapeutic potential 
6,35, these inhibitors interfere with hepatic and intestinal MTP activity which may be accompanied 
by side effects including deficiency of lipid soluble vitamins 5. Targeted ribozyme therapy as 
proposed in this study may, with its liver and MTP specific mode of action, perform better in this 
regard, while its sustained inhibition also favorably contrasts with that of previously described 
antisense drugs 36.  
 In conclusion, a ribozyme has been designed which specifically targets muMTP and 
effects cleavage of MTP mRNA at the predicted site. While a CMV driven adenovirus construct 
was ineffective, a tRNAmet promoter construct appeared to be capable of lowering muMTP 
expression in vitro by >50%. This ribozyme construct may thus proof a valuable tool for future 
mechanistic studies on MTP but also as starting point for gene therapy strategies aiming at MTP 
lowering  
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Abstract 
 
 Genetic studies have indicated that in humans znf202 is functionally linked to 
hypoalphalipoproteinemia and recent in vitro studies have shown that the zinc finger protein 
Znf202 binds to and represses the promoter activity of lipid related genes such as ABCA1, apoA4, 
and apoE. However, the net effect of modulation of Znf202 expression on lipid metabolism 
remains unclear. In this study we have verified whether interspecies differences exist in Znf202 
regulation that prelude the mice as testing species for Znf202 function. Infection of the murine 
hepatoma cell line, mhAT3F2, with Ad-Znf202 led to a significant up to 50% reduction in the 
expression of the apoE/C1/C2 and the apoA1/C3/A4/A5 gene clusters. Promoter deletion analysis 
of the mouse apoE promoter revealed that Znf202 caused a more than two-fold reduction in apoE 
promoter activity. The repressive activity could be localized to a region spanning nucleotides –
705 and –362, which includes two putative Znf202 response elements. The Znf202 response 
elements are considerably more upstream than that in the human apoE gene, whereas similar 
repressive effect of Znf202 on the mouse apoE gene was observed. These findings support that 
Znf202 governs the transcription repression of key genes in lipid metabolism and that mouse 
models might be a valuable tool to assess the role of Znf202 in lipid metabolism. 
 
Introduction 
 
To date, several genes have been identified that transcriptionally regulate the expression 
of lipid related genes. The gene of one such transcription factor, the zinc finger protein znf202, 
was found in the locus linked to heritable hypoalphalipoproteinemia in Utah pedigrees 1,2. It 
encodes a protein belonging to the subfamily of Cys2-His2 zinc-finger proteins which contain a 
Leucine-rich domain known as SCAN and Krueppel-associated box (KRAB) 1,3. Although the 
function of the individual domains are still under investigation, the presence of a KRAB domain 
in Znf202 indicates that it may function as a transcriptional repressor 4. The consensus DNA 
motif of the Znf202 response element has been characterized as GGGGT (GnT) 5. Based on 
presence of this consensus site in various promoters, Znf202 was suggested to have a broad range 
of target genes involved in lipid metabolism. In vitro studies have confirmed that Znf202 
overexpression is accompanied by a repression of apoE, apoA4, ABCA1, and ABCG1 promoter 
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activity and that during monocyte differentiation and foam cell formation Znf202 expression is 
inversely correlated with apoE and ABCA1 expression 5-7. These findings provide insight in the 
important role of Znf202 in lipid metabolism, but the overall phenotypic effect of modified 
Znf202 expression is still hard to predict. Since znf202 and their target genes are strongly 
conserved between mice and humans, mouse models could be a valuable tool to investigate the 
putative role of Znf202 in lipid metabolism. The different response of cholesterol 7α-hydroxylase 
(cyp7A1) expression upon liver X receptor (LXR) activation between both species has illustrated 
that before extrapolating transcriptional regulatory pathways between species the regulatory 
control in both species should first be firmly established 8,9. 
Therefore, in this study we set out to investigate the transcriptional regulation of murine 
apoE by Znf202. Since promoter-reporter assays have demonstrated the control of Znf202 over 
the human apoE promoter and an inverse correlation between endogenous Znf202 and apoE 
expression during monocyte differentiation was shown, we analyzed the mouse apoE promoter 
for Znf202 consensus sites.  We found a strongly conserved region of 200 bp upstream of the 
transcription initiation site, which included a TATA box, a GC box, and a Znf202 binding motif. 
Our results show that the activity of the apoE promoter is reduced in the presence of Znf202 in a 
hepatic related cell type.  The region of the apoE promoter ranging from nucleotides -705 to -362, 
was required for repressive action by Znf202 and the transcription factor co-localized with the 
Znf202 consensus sites within that region. Although this report confirms repressive activity of 
mouse Znf202, we found a species-specific difference in the promoter region of apoE. 
 
Material and Methods 
 
Cell Culture 
Mouse hepatoma mhAT3F2 cells 10 were cultured in Dulbecco’s Modified Eagle’s Medium with F-12 (cat. no. 
31331, Gibco) supplemented with 10% fetal calf serum (Gibco), 100 IU/ml Penicillin, 100 µg/ml Streptomycin, 20 
mM GlutaMAX I , 400 nM Insulin (Sigma), 10 nM Dexamethasone (Sigma). Per.C6 and 911 11,12 cells were both 
cultured in Dulbecco’s Modified Eagle’s Medium (cat. no. 41966, Gibco), supplemented with 10% fetal calf serum 
(Gibco), 100 IU/ml Penicillin, 100 µg/ml Streptomycin, 2 mM GlutaMAX I (Gibco), with the difference that for 
Per.C6 cells 10 mM MgCl2 was added. For large scale production of recombinant adenovirus in Per.C6 cells the 10% 
fetal calf serum was substituted with 2% horse serum (Gibco).  
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Construction of expression constructs 
Mouse Znf202m1 was obtained from liver cDNA of C57Bl/6JIco by PCR (nucleotide positions 186 to 2208, 
GenBank accession number AF292648), with forward primer 5’ -GGTACCATAACACCCAAGAGCCAGGA -3’ 
containing a KpnI site and a reverse primer 5’ -TCTAGACAGAACCCATCCGTCTCAGT -3’ containing a XbaI 
site. The amplicon Znf202 was cloned into pShuttleCMV and pAdTrackCMV via these restriction sites 13. Sequences 
were verified by sequence analysis using ABI 3700 (LGTC, Leiden). 
 
Construction of reporter gene constructs 
The apolipoprotein E promoter (GenBank accession number D00466) was cloned from  cosmid mAPOE/B1 cos27 
(C2RB) by PCR. Two reverse primers were designed, one targeting nt  1020 of exon 1, and one targeting nt 1801 of 
exon 2, immediately upstream of start codon, because intron 1 contains an Intron Regulatory Element 1 (IRE 1). The 
mouse promoter was sub-divided in 6 sections and forward primers were chosen accordingly (table 1).  
The amplicons were cloned into the pCR.2.1 TOPO vector of the TOPO TA Cloning kit (Invitrogen). Subsequently, 
KpnI-HindIII fragments were cut out of the pCR.2.1 vector and inserted into KpnI-HindIII restricted pGL3-Basic 
(Promega). All promoter fragments in the resulting reporter gene constructs were verified by sequencing (LGTC, 
Leiden). 
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6able 1. primers used to generate promoter constructs 
primer Sequence 
 
mApoEp-705FW 5’ CCGGTACCGGCTTGAGAGTGGAAAATGC 
mApoEp-362FW 5’ CCGGTACCAGGGATCCCAGAACAACGAT 
mApoEp-218FW 5’ CCGGTACCCCAAGGCCTGGATTATTCAA 
mApoEp-90FW 5’ CCGGTACCTCGTGACAGCGTGCACAG 
mApoEp-34FW 5’ CCGGTACCCCTATAATTGGACCGGTCTGG 
mApoEp-9FW 5’ CCGGTACCCGATCCCCTGCTCAGACC 
              KpnI 
  
mApoEpEx1RV 5’ GGGAAGCTTGTCCTTAGCCTCCAGGGTCT 
mApoEpEx2RV 5’ GGGAAGCTTCGCAATTGTGATTGGCC 
               HindIII  
uciferase reporter assays 
ransient transfections in mhAT3F2 cells were performed in triplicate in 6-well plates using  Fugene 6 Transfection 
eagent (Roche Molecular Biochemicals). Luciferase activity of the different promoter-reporter constructs and a 
romoterless pGL3-basis serving as control was measured by co-transfecting the cells with 200 ng of a reporter gene 
onstruct and 100 ng of pCMV-LacZ. After 24 h, the cells were lysed after 24 h with reporter lysis buffer (Promega) 
nd after centrifugation of 2 min, supernatant was used for determining β-galactosidase normalized luciferase 
ctivity by adding 100 µl luciferyl-CoA (Promega) to 20 µl of cell extract in a monolight luminometer (BD 
iosciences). β-galactosidase was measured in a 96-well microtiter plate using the β-Galactosidase Enzyme Assay 
ystem in reporter lysis buffer (Promega). Absorbance at 405 nm was determined in a microplate reader. The effect 
f Znf202 on transcription regulation of the reporter gene constructs was determined by co-transfecting the cells with 
6 
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100 ng of a reporter gene construct and 1900 ng of the expression vector pShuttleCMV-Znf202 or an empty 
pShuttleCMV control vector. Luciferase activities were measured as described above and normalized for protein 
concentrations using BCA System (Pierce). 
 
Whole cell extract preparation and electrophoretic mobility shift assays 
911 cells were transfected with 5 µg pAdTrackCMV-Znf202 or control plasmid on 10 cm dishes using 
LipofectAMINE plus kit. After 40 hours cells were harvested, and cell pellets were resuspended in equal volumes of 
a lysis buffer (20 mM Hepes, 600 mM KCl, 0.2 mM EDTA, 1mM DTT, 0.5 mM phenylmethylsulfonyl fluoride 
(PMSF), 0.5 mM leupeptine, 0.5 mM Aprotinin, 0.5 mM pepstatinA, 0.5 mM 4-(2-amino ethyl)benzene sulfonyl 
fluoride (ABSF)). This mixture was agitated gently for 30 minutes at 4ºC and centrifuged for 10 minutes at 4ºC. 
Supernatant was collected and an equal volume of a glycerol buffer was added (1 (20 mM Hepes, 40% glycerol, 0.2 
mM EDTA, 1mM DTT, 0.5 mM phenylmethylsulfonyl fluoride (PMSF), 0.5 mM leupeptine, 0.5 mM Aprotinin, 0.5 
mM pepstatinA, 0.5 mM 4-(2-amino ethyl)benzene sulfonyl fluoride (ABSF)). Protein concentrations were 
determined using Bradford assay (BioRad). The DNA-binding activity of mouse Znf202 in whole cell extracts was 
studied by means of EMSA. Double-stranded DNA probes containing the Znf202 binding sites, the consensus GnT 
oligonucleotide, the putative -564 and -678 Znf202 binding oligonucleotides, as well as a control unrelated fragment 
containing the pleiohomeotic (PHO) consensus binding site were used for gel shift analyses after end-labeling of 
each probe with [ -32P]ATP and T4 polynucleotide kinase. The sequences of  the GnT, -564, -678, and PHO 
oligonucleotides were 5'- GTGGGGTGGGGGTGGGGGGTCC-3', 5'- GCTCTGTAGGGGTAGCTCTTCC-3', 5'- 
TGCACATGCAGGGGTGCACACC -3' and 5'- CCGGCGCAGCCATTAAGGAGG -3' respectively. 32P labeled 
oligonucleotide probes ( 20 fmol) were incubated with 0.1 – 0.6 µg of whole cell extract of control or Znf202 
overexpressing cells for 30 min at room temperature in 25 µl of reaction mixture containing 20 mM HEPES–KOH 
pH 7.9, 5 mM MgCl2, 75 mM KCl, 1 mM DTT, 0.1 mM EDTA, 2 µg of BSA and 2 µg of poly(dI–dC)· poly(dI–dC) 
as competitor DNA.  Specificity of binding was determined by competition experiments in the presence of a 50-fold 
excess of unlabeled GnT, -564, or -678 oligonucleotide. Reaction mixtures were loaded on native 6% polyacrylamide 
gels, run in 0.5x Tris-Glycine at 200 V at 4°C, and visualized by autoradiography. 
 
Adenoviral vectors 
Recombinant adenoviral plasmids were generated by homologous recombination with pAdEasy1 in BJ5183 cells as 
described previously 13. Correct clones were propagated in STBL2 cells (Life Technologies). For the production of 
Ad-Znf202 Per.C6 cells were transfected with 3 µg Pac-I-linearized adenoviral construct on 35 mm dishes using 
LipofectAMINE PLUS kit as described by the manufacturer (Life Technologies). After 16 hours transfection 
medium was replaced by growth medium. Transfected cells were harvested at day 7 post-transfection and after three 
cycles of freeze-thaw the lysate was used for large-scale production of Ad-Znf202 in Per.C6 cells. Virus was purified 
by CsCl centrifugation and subsequently dialyzed. Final yields as assessed by plaque assay in 911 cells were 
approximately 2 × 1010 plaque forming units (pfu)/ml. Control virus Ad-LacZ was produced as described previously 
14. MhAT3F2 cells were seeded in a 12-wells plate and grown to a confluency of 70%. Cells were infected with 
either Ad-Znf202 or control Ad-LacZ (MOI=100).  
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Real time quantitative PCR analysis 
Total RNA from mhAT3F2 infected cells was isolated by using the Trizol method according to the manufacturer’s 
protocol (Eurogentec). Purified RNA was treated with RQ1 RNase-free DNase (Promega, 1 units/ 2 µg of total RNA) 
and reverse transcribed with SuperScript II Reverse Transcriptase (Invitrogen) according to the manufacturer’s 
protocol. Quantitative gene expression analysis was performed on an ABI prism7700 Sequence Detection System 
(Applied Biosystems) using SYBR Green as described earlier 15. PCR primer sets (table 2) were designed via Primer 
Express 1.7 software with the manufacturer's default settings (Applied Biosystems) and were validated for 
amplification efficiency. The absence of genomic DNA contamination in the RNA preparations was confirmed in a 
separate PCR reaction on total RNA samples which were not reverse transcribed. Hypoxanthine-guanine 
phosphoribosyl transferase (HPRT) was used as the standard housekeeping gene. 
 
Data Analysis—The significance of differences in relative gene expression numbers Ct (Ct(HPRT)–Ct(target gene))  
measured by real time quantitative PCR was calculated using a two-tailed Student's t test. Probability values less than 
0.05 were considered significant. 
 
Table 2. Primers used for gene expression analysis 
 
Gene GenBank 
Acces. 
Forward Primer Reverse Primer Size 
36B4 X03672 GGACCCGAGAAGACCTCCTT GCACATCACTCAGAATTTCAATGG 85 
ApoA1 NM_009692 GGCAGAGACTATGTGTCCCAGTT CCCAGTTTTCCAGGAGATTCAG 97 
ApoA4 XM_134754 GGAGGCTGTAGAACAGTTTCAGAAG TCCCCAAGTTTGTCCTGGAA 94 
ApoA5 BC011198 GAGCAAAGGCGTGATGGG TGCTCGAAGCTGCCTTTCA 66 
ApoC1 BC019398 CGGGCAGCCATTGAACATA TTGCCAAATGCCTCTGAGAAC 77 
ApoC2 NM_009695 TTGCCAAAGACCTGTACCAGAA GCCGAGCTTTTGCTGTACATG 78 
ApoC3 NM_023114 CATCTGCCCGAGCTGAAGA GCTTGTTCCATGTAGCCCTGTAC 93 
apoE M12414 AGCCAATAGTGGAAGACATGCA GCAGGACAGGAGAAGGATACTCAT 130 
Cyclophilin M60456 TCGGAGCGCAATATGAAGGT AAAAGGAAGACGACGGAGCC 65 
GAPDH NM_008084 TCCATGACAACTTTGGCATTG TCACGCCACAGCTTTCCA 103 
HPRT J00423 TTGCTCGAGATGTCATGAAGGA AGCAGGTCAGCAAAGAACTTATAG 91 
Znf202 AF292648 GTGTGGCCGCTCCTTCAG GGGCGATGATCCTGTACTGG 79 
 
Results 
 
Genes within the apoE/C1/C2 and apoA1/C3/A4/A5 clusters are downregulated upon 
Znf202 overexpression. 
We analyzed the effect of Znf202 overexpression on the apoE/C1/C2 and 
apoA1/C3/A4/A5 gene clusters in the mouse hepatoma cell line mhAT3F2.  To study the effect of 
Znf202 overexpression in cells we constructed a recombinant adenovirus containing the mouse 
Znf202 gene. MhAT3F2 cells were transduced with Ad-Znf202 at a multiplicity of infection of 
100 (MOI=100). After 24 hours the cells were harvested and total RNA was isolated for 
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quantitive real time PCR analysis (Fig. 1). GAPDH, cyclophylin, or 36B4 expression remained 
unaffected by Znf202 overexpression. However, Znf202 overexpression did result in a significant 
downregulation of apolipoprotein genes from both clusters. RNA levels were reduced up to 50% 
(apoC2 and apoC3) and reached significance for all genes (p<0.05) except apoA5. 
 
 
Figure 1
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. Overexpression of Znf202 in mhAT3F2 cells leads to repression of genes that are situated within the 
/C2 and apoA1/C3/A4/A5 gene clusters. MhAT3F2 cells were transduced with Ad-Znf202 (black bars) or 
 (grey bars)(MOI=100) and RNA levels were measured via quantitative real time PCR at 24 hours post-
on. Data represent average of four transductions for each group (mean ± S.D) and expressions are relative 
 
ation of  repressive effect of Znf202 on mouse apoE promoter to -705/-362 region. 
runcation of the upstream promoter fragment was based on the position of putative 
responsive GnT sites. As a measure of the promoter activity we determined luciferase 
of the various apoE promoter-reporter constructs in mhAT3F2 cells at 24 hours post-
tion (Fig. 2). Expression values were normalized for transfection efficiency, by co-
tion with pCMV-LacZ and β-Galactosidase assay serving as an internal reference. 
ison of the relative luciferase activity of the reporter constructs revealed that the presence 
n-1 had a repressive effect on the apoE promoter activity. In fact, the reporter construct 
ng the promoter sequence -90/+821 completely lacked activity, whereas activity was 
 be 40-fold increased in comparison with the promoterless pGL3-basic upon deletion of 
. Further, the presence of nucleotide sequences spanning -362 to -90 was seen to enhance 
r activity, while the addition of region -705/-362 attenuated the enhanced activity to up to 
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Figure 2. Promoter activity of truncated fragments of the mouse apoE promoter. MhAT3F2 cells were 
tranfected with reporter gene vectors for the mouse apoE promoter. Co-transfection with pCMV-LacZ served as 
a control for transfection efficiency. Luciferase activity was normalized for β-galactosidase activity. 
 
-fold. To investigate the repressive effect of mouse Znf202 on the apoE promoter activity we 
o-transfected promoter reporter constructs with intron-1 deletion and Znf202 expression vector 
Fig. 3). Znf202 appeared to repress transcriptional activity of the apoE promoter only when the 
omplete -705/+24 region was present. Deletion of the 5’ end (-705/-362) abolished the 
epressive effect of Znf202 on the ApoE promoter activity. 
 
igure 3. Repressive effect of Znf202 on mouse apoE promoter activity only when -705/-362 region is present. 
hAT3F2 cells were transiently cotransfected with the indicated reporter gene constructs and Znf202 expression 
ector. The reporter gene construct contained the mouse apoE promoter without downstream intron-1 (-705 to +24) 
r truncated variants. As control expression vector pShuttleCMV-empty was used. After 24 hours cells were 
arvested and luciferase activities (mean ± S.D.) measured and normalized for protein concentration. 
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Figure 4. The Znf202 specifically binds to the -678 and -564 sites within the -705/-362 region of the mouse 
apoE promoter. DNA fragments used in this study containing the consensus or putative Znf202 binding sequence. 
The putative consensus sequences are shown underlined (A). EMSA with labeled DNA fragments GnT (lanes 1-10), 
-678 (lanes 11-20), -564 (lanes 21-30), and PHO (lanes 31-35) described above (B). Reactions contained the 
indicated amount (0.1-0.6 µg) of whole cell extract made from either control 911 cells (lanes 2, 5, 8, 12, 15, 18, 22, 
25, 28, 32, and 34), or from 911 cells overexpressing Znf202 protein (lanes 3, 4, 6, 7, 9, 10, 13, 14, 16, 17, 19, 20, 
23, 24, 26, 27, 29, 30, 33, and 35). Competition experiments using 50-fold excess of unlabeled GnT oligonucleotide  
(lanes 4,7 and 10),  -678 oligonucleotide (lanes 14,17 and 20), or -564 oligonucleotide (lanes 24,27 and 30) 
confirmed the specificity of Znf202 binding. Arrowheads indicate the mobility of unbound DNA and Znf202 protein 
bound DNA. 
 
Znf202 binds to GnT sites within the -705/-362 region. 
We demonstrated above that Znf202 has a repressive effect on apoE expression and that 
this activity is restricted to the -705/-362 region. This region contained two putative GnT sites at 
positions -678 and -564, and we have examined these consensus sites for their capacity to bind 
Znf202 by EMSA. Thus, 911 cells were transfected with pAdTrackCMV-Znf202 or 
pAdTrackCMV (empty vector). Since these plasmids also carry the enhanced GFP reporter gene, 
the transfection efficiency could be easily assessed by fluorescent microscopy showing that 50% 
of the cells were GFP positive. Whole cell extracts were prepared at 40 hours post-transfection 
and Znf202 binding to the two 32P-labeled double-stranded oligonucleotide probes -678 and -564 
(-689/-668 and -573/-552) mimicking the alleged binding sites, was assayed (Fig 4A). As 
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controls we used the Znf202 binding fragment of human ApoA4 promoter containing three 
consecutive GnT sites 7 and an unrelated probe containing a PHO consensus site. The GnT 
control probe (Fig. 4B, lanes 1-10) induced a clear mobility shift indicative of the formation 
DNA-protein complexes in extracts from Znf202 overexpressing 911 cells (lanes 3, 6, 9). The 
binding to the probe was specifically competed by 50-fold excess of unlabeled GnT probe (lane 
4, 7, 10). Similar mobility shifts were observed for the 32P-labeled -678 (lanes 11-20) or -564 
probe (lanes 21-30) after Znf202 overexpression.. In analogy to the reference probe, the 
specificity of binding was confirmed by displacement by the 50-fold excess of either unlabeled -
678 probe or -564 probe. Finally, the extract was unable to form DNA-protein complexes with an 
irrelevant PHO consensus probe, even at high concentrations (lanes 32 and 33). These results 
clearly show that Znf202 specifically binds to its predicted consensus sites at nucleotide -678 and 
-564 within the -705/-362 fragment of the apoE promoter. 
 
Discussion 
  
 The linkage of the znf202 gene to familial hypoalphalipoproteinemia together with the 
identification of several lipid related target genes of Znf202, illustrate the important role of 
Znf202 in lipid and, in particular, HDL-metabolism 1,2. Previous reports have demonstrated that 
Znf202 represses the promoter activity of apoE and apoA4 5,7, two members of the apoE/C1//C2 
and apoA1/C3/A4/A5 gene cluster, respectively. As transcriptional regulation may differ among 
species, and as these gene clusters show a strong resemblance with their murine counterparts, we 
analyzed the effect of mouse Znf202 on the expression of both gene clusters in a mouse 
hepatoma cell line. We demonstrate that all gene members found in the two gene clusters except 
apoA5 were repressed in mhAT3F2 cells upon infection with Ad-Znf202.  
To investigate the mechanism of transcriptional repression by Znf202 we performed a 
promoter deletion analysis of the murine apoE gene. The repressive effect of Znf202 was 
previously demonstrated in the -322 to +18 region of the human apoE gene and a putative Znf202 
consensus site was identified at position -177 5.  Screening of the -705-+821 proximal region of 
the mouse ApoE gene for potential Znf202 binding sites revealed five GnT consensus sites 
(positions -678, -564, -338, -315, -160). A series of promoter luciferase constructs were 
generated at which truncation of the mouse ApoE promoter was based on the position of these 
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GnT sites, and either contained or lacked intron 1 (+42 to +801), This intron was reported to 
encompass regulatory elements that may influence Znf202 mediated repression 16.  
While the presence of intron 1 led to a 2-fold reduction in ApoE promoter activity in mhAT3F2 
cells, it did not affect the overall pattern of expressional regulation. A sharp reduction in 
promoter activity was observed upon deletion of the –362/-90 region, which may be attributed to  
enhancer elements located in these region 16,17. , Truncation of -705 to -362 was accompanied by 
a strong 3-fold increase in promoter activity  suggesting the presence of suppressor elements in 
that region. More relevant, Znf202 responsiveness of the mouse apoE promoter activity was 
ablated upon removal of nt -705/-362. Further analysis established that Znf202 binds specifically 
to the two GnT sites within that region, to repress mouse apoE expression, we demonstrate here 
that the Znf202 responsive elements of the mouse ApoE promoter are located far more upstream 
than that of the human counterpart. Species specific differences in promoter set-up translating 
into an altered promoter function or responsiveness to modulators of gene expression have been 
described for several genes such as the osteocalcin, toll-like receptor 3 and cyp7A1 9,18,19.  
In conclusion, although the promoter architecture of the apoE gene, and in particular the 
location of the Znf202 response elements, appears to differ between mice and men , our data 
show that mouse apoE expression is regulated by Znf202 as well. In addition, we demonstrate 
that Znf202 overexpression affects the endogenous expression level of lipid related genes in mice 
to a similar extent as in men, establishing the mouse as an adequate in vivo model for 
mechanistic studies on Znf202 regulation of lipid metabolism.  
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Abstract 
 
Background/Aims: The zinc finger protein Znf202 has been described as a negative transcrip-
tional regulator of lipid related genes and has been linked with hypoalphalipoproteinemia. In this 
study we are the first to map Znf202 function in lipid metabolism in vivo. Methods: Hepatic 
overexpression of Znf202 in wild type and Ldlr-/- mice was achieved by adenovirus gene 
transfer. Blood samples were taken at day 4 and 5 post-infection, mice were sacrificed and liver 
biopts obtained at day 5. Sera were analyzed for lipid and lipoprotein profile, while liver biopts 
were used for histological, gene expression, and lipid analysis. Results: Znf202 gene transfer to 
Ldlr-/- mice resulted in marked hypercholesterolemia (>2-fold increase of serum total 
cholesterol) and hypotriglyceridemia (4-fold reduction in serum triglycerides) (P<0.05), which 
was attributable to an increase in cholesterol-rich, triglyceride-poor VLDL and a concomitant 
drop in HDL levels. Furthermore, Znf202 overexpression caused severe steatosis and led to a 
surprising 3-fold increase in hepatic Apoc2 and Apoa5 expression (P< 0.05), whereas that of 
other genes with Znf202 responsive elements remained unaffected. As Apoc2 and Apoa5 
overexpression is associated with hypotriglyceridemia, this could at least partly explain the 
observed phenotype. While Znf202 overexpression in wild type mice effected a similar increase 
in Apoc2 and Apoa5 expression and drop in HDL levels, this was not accompanied by changes in 
serum VLDL nor by steatosis. In wild type both not in Ldlr-/- mice, Znf202 overexpression 
sharply increased cholesterol 7α-hydroxylase expression (P<0.05) and activity (P<0.001), which 
raises the intriguing premise that this gene may be instrumental in Znf202 induced responses. 
Conclusion: Znf202 overexpression in vivo reveals an important role of this transcriptional 
regulator in liver lipid homeostasis, while establishing the proposed key function in the control of 
HDL homeostasis. 
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Introduction 
 
 Hypoalphalipoproteinemia, characterized by subnormal levels of serum HDL, is the most 
common lipoprotein abnormality in patients with coronary heart disease (CHD) 1. HDL could be 
atheroprotective on its own account by acting as lipid acceptor in reverse cholesterol transport 
from the periphery to the liver and by its anti-inflammatory properties. In addition, low HDL 
levels often are causally linked to other risk factors including diabetes and hyperlipidemia 2. 
Hypoalphalipoproteinemia has been associated in part with an impaired cellular cholesterol efflux 
caused by mutations in the ABCAI gene 3. 
The Znf202 gene has been identified in a chromosomal region linked to heritable 
hypoalphalipoproteinemia in Utah pedigrees 4,5. The Znf202 protein is a Cys2-His2 zinc-finger 
protein family member and contains a leucine-rich domain known as SCAN and a Krueppel-
associated box (KRAB) 6,7. Although the specific function of these domains is still under 
investigation, the presence of a KRAB domain in Znf202 is suggestive of transcriptional 
repressor activity 8. This is corroborated by in vitro findings showing repressional activity of 
Znf202 on a range of target genes involved in lipid metabolism including Apoe, Apoa4, ABCA1, 
and ABCG1 in hepatoma cells 5 as well as monocytes 9. It was shown that Znf202 interacts with 
GnT response motifs in the respective promoter regions of these genes. Despite the relatively 
detailed insight in the range of Znf202 responsive genes in vitro, little is known of Znf202 
mediated gene regulation in vivo in specific tissues. Moreover, the contribution of Znf202 to the 
regulation of serum lipid and lipoprotein metabolism is up till now unclear. 
 In the present study, we have investigated the effect of Znf202 overexpression in vivo 
both in normo- (C57Bl/6) as well as in hyperlipidemic (Ldlr-/-) mice. To this end, we have 
generated an adenovirus vector carrying the mouse Znf202 gene (Ad.Znf202) and assessed the 
effect of hepatic gene overexpression in both mouse strains on serum lipid and lipoprotein levels 
and on the hepatic gene expression profile. A marked difference was found between the in vitro 
versus in vivo effect of Znf202 overexpression on the mRNA levels of key genes involved in 
lipid metabolism. While Znf202 overexpression in vivo reduced HDL levels in hyperlipidemic 
Ldlr-/- as well as wild type mice, this was accompanied by perturbed lipid homeostasis in 
hyperlipidemic mice only. The changes in expression of specific genes differed between Ldlr-/- 
and C57Bl/6 mice providing a potential explanation for the differences in serum cholesterol and 
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TG responses. Our data clearly demonstrate that the transcription factor ZNF202 can act as a key 
regulator in lipoprotein metabolism. 
 
Material and Methods 
 
Generation of Adenoviral Constructs 
Mouse Znf202m1 (nucleotide positions 186-2208; GenBank accession number AF292648) was obtained from liver 
cDNA of C57Bl/6JIco by PCR. Forward (5’ GGT.ACC.ATA.ACA.CCC.AAG.AGC.CAG.GA) and reverse primers 
(5’-TCT.AGA.CAG.AAC.CCA.TCC.GTC.TCA.GT) contained a KpnI and XbaI site, respectively, and Znf202 
amplicon was cloned into pShuttleCMV via these restriction sites. Recombinant adenoviral plasmids by homologous 
recombination with pAdEasy1 were generated in BJ5183 cells as described by He et al. 10. Correct clones were 
propagated in STBL2 cells (Invitrogen Life Technologies, Breda, The Netherlands). For the production of 
Ad.Znf202 Per.C6 cells (Crucell, Leiden, NL) were transfected with 3 µg Pac-I-linearized adenoviral construct on 35 
mm dishes using LipofectAMINE PLUS kit according to the manufacturer’s protocol (Life Technologies). After 16 
hours transfection medium was replaced by growth medium. Transfected cells were harvested at day 7 post-
transfection and after three freeze-thaw cycles the lysate was used for large-scale production of Ad.Znf202 in Per.C6 
cells. Virus was purified by CsCl centrifugation steps and dialysis. Final yields were assessed via a plaque assay in 
911 cells and titers were obtained of approximately 2 × 1010 plaque forming units (pfu)/ml. The construction of 
control virus Ad-mock (Ad-LacZ) has been described previously 11. 
 
Animals and Adenovirus Injection 
All animal work was approved by the Ethics Committee for Animal Experiments of the Leiden University and the 
experimental protocols complied with the national guidelines for use of experimental animals. Male C57Bl/6JIco 
(Sylvius laboratoria, Leiden, The Netherlands) and Ldlr-/- mice on a C57Bl/6JIco genetic background (TNO-PG, 
Leiden, The Netherlands) were given a standard mouse diet Chow (Hope Farms, Woerden, NL) and housed under 
standard conditions in conventional cages with free access to water and food. 
Recombinant adenovirus, 2 × 109 pfu in 200 µl of PBS, were administered by injection into the tail vein of mice at 
the age of 28-32 weeks. Blood samples were taken via tail bleeding 3 days prior to infection and at day 4 and 5 post-
infection. At day 5 after bleeding, mice were sacrificed, liver sections were removed and immediately deep-frozen in 
liquid nitrogen and stored at -80°C. Cryosections were prepared from liver samples and stained with Oil Red-O 
(Sigma Diagnostics, St. Louis, MO) and hematoxylin (Sigma Diagnostics). 
 
Determination of mRNA Levels 
Total RNA was isolated from the caudate liver lobes by the RNA Instapure method according to the manufacturer’s 
protocol (Eurogentec SA, Seraing, Belguim). Purified RNA was treated with RQ1 RNase-free DNase (Promega, 1 
units/ 2 µg of total RNA) and reverse transcribed with SuperScript II Reverse Transcriptase (Invitrogen, Breda, The 
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Table-1: Primers sets used for quantitative real-time RT-PCR 
Netherlands) according to the protocols supplied by the manufacturers. Quantitative gene expression analysis was 
performed on an ABI prism7700 Sequence Detection System (Applied Biosystems, Foster City, CA) by SYBR 
Green as described previously 12. PCR primers (table I) were designed on the basis of Primer Express 1.7 software 
with the manufacturer's default settings (Applied Biosystems) and validated for identical efficiencies. The absence of 
genomic DNA contamination in the RNA preparations was verified by PCR of total RNA samples that had not been 
subjected to reverse transcription. Hypoxanthine-guanine phosphoribosyl transferase (HPRT) and acidic ribosomal 
phosphoprotein P0 (36B4) were used as standard housekeeping genes. Ratios of target to control gene expression 
(relative gene expression numbers) were calculated by subtracting the Ct of the target gene from the Ct of HPRT and 
raising 2 to the power of this difference. Ct values are defined as the number of PCR cycles at which the fluorescent 
signal during the PCR reaches a fixed threshold. Target gene mRNA expressions are thus expressed relative to HPRT 
expression. 
 
Lipid and lipoprotein analysis  
Blood was collected from each individual mouse through tail bleeding in diethyl-p-nitro phenyl phosphate (paraoxon) 
coated capillary tubes, after a 4-hour fasting period 13. Total serum cholesterol (kit No.236691, Boehringer-
Mannheim) and triglycerides (kit No. 337-B, Sigma Chemical Co) were measured enzymatically. Lipoprotein 
distribution was determined by fast performance liquid chromatography (FPLC).  A plasma pool was obtained from 
each group of mice before adenovirus injection and 4 days after adenovirus injection and was diluted 2 to 5-fold with 
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PBS. A volume of 70 µl was injected onto a Superose6 column (3.2 x 30 mm, AKTA-system, Pharmacia, Uppsala, 
Sweden). Elution fractions of 50 µl were collected and assayed for cholesterol and triglyceride levels as described 
above. For measurement liver lipids, frozen (N2) liver samples were homogenized and samples were taken for 
measurement of protein content (Lowry). Lipids were extracted from the homogenate according to Bligh and Dyer. 
After evaporation, lipids were dissolved in a 2% Triton-X-100 solution and cholesterol and triglyceride levels were 
determined as described above. 
 
Cholesterol 7α-hydroxylase enzyme activity assay 
Cyp7A1 enzyme activities in isolated liver microsomes were determined essentially according to Chiang 14 by 
measuring the conversion of cholesterol into 7 -hydroxycholesterol. In short, liver homogenate (750 ug protein) was 
incubated in 1 ml of buffer containing 0.1 M potassium phosphate, pH 7.2, 50 mM NaF, 5 mM DTT, 1 mM EDTA, 
20% glycerol (w/v), and 0.015% (w/w) CHAPS. Twenty µl of 1 mg cholesterol in 45% (w/v) hydroxypropyl-ß-
cyclodextrin was added and the mixture was incubated for 10 min at 37°C under gentle agitation. Regenerating buffer 
(200 µl) was added, containing 10 mM sodium isocitrate, 10 mM MgCl2, 1 mM NADPH, and 0.15 U isocitrate-
dehydrogenase at 37 °C. After 20 min of incubation, a stop solution (60 µl) containing 20% sodium cholate and 1 µg 
20 -hydroxycholesterol, which served as an internal standard, was added. Steroid products were oxidized for 45 min 
in 100 µl buffer containing 0.1% cholesterol oxidase, 10 mM K2HPO4, 1 mM DTT, and 20% glycerin at 37 °C, and 
the reaction was stopped by addition of 2 ml ethanol. Cholesterol metabolites from this reaction mixture were 
extracted in petroleum ether and the ether layer was evaporated under a stream of nitrogen. Residues resuspended in 
a mixture of 60% acetonitril, 30% methanol and 10% chloroform (v/v) were analyzed by using C-18 reverse phase 
HPLC on a Tosohaas TSK gel-ODS 80TM column equilibrated with 70% acetonitrile and 30% methanol at a flow 
rate of 0.8 ml/min. The amount of products formed was determined by monitoring the absorbance at 240 nm. Peaks 
were integrated using Data Control software (Cecil Instruments, UK). 
Data Analysis– The significance of differences in relative gene expression numbers among the different liver cell 
types, from three different cell isolations, measured by real time quantitative PCR was calculated using a two-tailed 
Student's t test on the differences in Ct (Ct(HPRT)–Ct(target gene)). Differences in lipid, lipoprotein and enzyme activity 
levels were analyzed statistically by Mann-Whitney-U test. Probability values less than 0.05 were considered 
significant. 
 
Results  
 
Lipid and lipoprotein levels after adenovirus mediated gene transfer of ZNF202  
 To address the role of Znf202 in lipid metabolism in vivo, we have overexpressed the 
Znf202 gene in two mouse strains: the normolipidemic C57Bl/6 (WT) and the hyperlipidemic 
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Ldlr-/- mouse by adenovirus mediated gene transfer.  Injection of Ad.Znf202 in Ldlr-/- and WT 
mice resulted in a significant hepatic overexpression of the transgene from ∆CT= -4 and -3 to 
∆CT= 5 and 6, respectively, and corresponding to a 29-fold induction of gene expression (relative 
expression compared to HPRT, using real-time PCR analysis).  Absolute expression levels of the 
housekeeping genes remained unaltered after Ad.Znf202 treatment.  
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igure 1: Hepatic Znf202 overexpression specifically alters serum cholesterol and triglyceride content in Ldlr-
- mice leaving WT mice unaffected. Blood samples were drawn from Ldlr-/- (n=4; left panels) and WT mice (n=4; 
ight panels) 4 or 5 days after injection with 2.109 pfu of Ad.Znf202 (filled bars) or with Ad-mock (open bars) and 
erived serum was analyzed for triglyceride and total cholesterol content. * and ** indicates P<0.05 and P<0.001, 
espectively. 
Serum lipid analysis revealed a significant 2-fold rise in serum total cholesterol levels in 
d.Znf202 treated Ldlr-/- mice on day 4 and 5 after gene transfer (P<0.001), whereas in  WT 
ice Znf202 overexpression did not affect serum TC levels (Fig.1). Surprisingly, the triglyceride 
evels were dramatically reduced by 4-fold (P<0.05) in Ldlr-/- mice only. Subsequent analysis of 
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the lipoprotein profile revealed that the elevated serum TC level in Ldlr-/- mice overexpressing 
Znf202 was attributable to an increased cholesterol content of the VLDL pool and a concomittant 
drop in cholesterol in the HDL fraction. Similar to the Ldlr-/- mice, WT mice displayed a marked 
reduction in HDL-cholesterol upon Znf202 overexpression (2.7 mg/ml for Ad-mock treated mice 
versus 0.7 mg/ml for Ad-Znf202 treated mice) (Fig. 2).  
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igure 2: Znf202 overexpression severely affects serum lipoprotein profiles in LDLr-/- mice and WT mice. 
lood samples were drawn from Ldlr-/- (n=4; left panels) and WT mice (n=4; right panels) 4 days after injection 
ith 2.109 pfu of Ad.Znf202 (triangles) or with Ad-mock (squares) and derived serum was analyzed for lipoprotein 
rofile by FPLC and the elution fractions were tested for triglyceride and total cholesterol content. 
epatic morphology and lipid content after adenovirus mediated gene transfer of ZNF202 
Histological analysis of livers isolated at day 5 post transduction from Ad.Znf202 and 
d.Mock treated Ldlr-/- and WT mice revealed some striking differences. Oil-red O staining of 
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Figure 3: Znf202 overexpression caused steatosis in Ldlr-/- mice only with an 2-fold increase of hepatic total 
cholesterol and triglycerides. Livers were isolated from Ldlr-/- and WT mice 5 days after injection with 2.109 pfu 
of Ad.Znf202 (filled bars) or Ad-mock (empty bars). Cryosections were prepared from Ldlr-/- liver samples and 
stained with Oil Red-O (A). Hepatic lipids were extracted from homogenized liver samples and cholesterol and TG 
concentrations were determined (B). Values are expressed as µg lipid per mg tissue protein and are means ± SD 
(N=4). * indicates p<0.05. 
liver sections demonstrated that Znf202 overexpressing livers obtained from Ldlr-/- mice were 
characterized by massive lipid deposition in intracellular vacuoles mainly (Fig.3A). As the liver 
morphology of Ad.Znf202 treated mice was highly reminiscent of steatosis, we assayed the liver 
lipid content quantitatively. As can be appreciated from figure 3B, Znf202 overexpressing livers 
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from Ldlr-/- mice contained >2-fold higher total cholesterol, cholesteryl esters, and triglyceride 
levels. In line with the normal liver morphology of WT mice injected with Ad.Znf202, no 
changes in the hepatic lipid content were found in the Znf202 overexpressing WT mice (Figure-
3B). 
 
Figure 4: Hepatic Znf202 
overexpression is accompanied 
by a changed expression of 
ApoA5 and ApoC2 mRNA in 
the liver. Liver was excised 
from Ldlr-/- (left panels) and 
WT mice (right panels) 5 days 
after injection with 2.109 pfu of 
Ad.Znf202 (filled bars) or Ad-
mock (empty bars) and total 
mRNAs was isolated and used 
for expression profiling by 
quantitative real time PCR. 
Gene expression is expressed 
relative to that of HPRT. Data 
are means ± S.D. of N=4 
determinations. Asteric indicates 
P<0.05. 
 
 
 
 
 
 
 
 
 
 
Gene expression profile after adenovirus mediated gene transfer of ZNF202 
  As Znf202 was reported to be a potent transcriptional repressor of various key genes in 
lipoprotein metabolism 5, we have mapped the hepatic expression profile of a range of potentially 
responsive genes at day 5 after Ad.Znf202 or Ad.mock treatment in Ldlr-/- and WT mice. 
Analysis of the Apoe/c1/c2 and Apoa1/c3/a4/a5 gene clusters showed that ZNF202 
overexpression increased the expression of Apoc2 and Apoa5 by 1.5 fold in WT mice and 3-fold 
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in Ldlr-/- mice (P< 0.05), but did not affect the expression of Apoe and Apoa1 both suggested to 
be Znf202 responsive in previous in vitro studies (Fig. 4A). Only Apoa4 expression was found to 
be significantly reduced upon ZNF202 overexpression in WT mice.  
 In search of a possible explanation for the elevated intrahepatic lipid levels, we 
determined gene expression levels of ABC family members, lipoprotein receptors (e.g. LRP, 
LDLr, SR-BI), and genes that are related to lipoprotein assembly (e.g. ApoB100, MTP) and 
cholesterol synthesis and degradation (e.g. HMG-CoA reductase, Cyp7A1, Cyp27, SREBPs) 
(Fig. 4B). Surprisingly, virtually none of the investigated genes displayed an altered expression 
level upon Znf202 overexpression, regardless whether obtained from Ldlr-/- or from WT mice. 
Cholesterol 7α-hydroxylase (Cyp7A1) was the only effector gene tested to display a differential 
effect in WT and Ldlr-/- mice upon Znf202 expression. In WT mice Znf202 increased Cyp7A1 
expression by >3-fold, but it did not change the expression in Ldlr-/- mice. 
Hepatic Znf202 overexpression also lead to transcriptional changes in nuclear receptor 
family members in Ldlr-/- mice but not in WT mice, although it remains to be determined 
whether this effect is causal in or secondary to the Znf202 induced intrahepatic lipid 
accumulation. The transcription factors HNF-4, PPARa, PPARd, LXRa/b and FXR were 
downregulated in Ldlr-/- mice by 25 to 60% (P<0.05) (Fig. 4C), while no effect was found in WT 
mice. 
 
 
 
 Figure 5: Liver analysis for Cyp7A1 activity 
in Ldlr-/- mice revealed a significant Cyp7A1 
induction in WT mice but not in Ldlr-/- mice. 
Liver was excised from Ldlr-/- and WT mice 5 
days after injection with 2.109 pfu of Ad.Znf202 
(filled bars) or Ad-mock (empty bars) and 
cyp7A1 activity was measured. Data are means 
± S.D. of N=4 determinations and ** indicates 
p<0.001. 
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 As a control for inflammatory responses inflicted by adenoviral gene transfer we have 
measured MARCO and CD68 mRNA levels in liver. The expression of both genes remained 
essentially unaffected upon Znf202 treatment (1.0±0.8 and 1.0±.0.6 for Ad-mock versus 0.7±0.4 
and 1.2±0.2 for Ad.Znf202 treated Ldlr-/- mice), thus confirming the histological finding that 
Znf202 did not promote massive leukocyte recruitment to the liver and excluding that an acute 
adenovirus elicited inflammatory response is underlying the observed phenotype in Ldlr-/- mice. 
The elevated hepatic Cyp7A1mRNA levels in Znf202 overexpressing WT mice prompted 
us to measure hepatic Cyp7A1 activity. The effect of Znf202 treatment on Cyp7A1 activity was 
even more pronounced and the activity was increased almost 6-fold from 0.78±0.03 to 4.0± 0.06 
mmol/mg/h in WT mice (P<0.001) (Fig. 5). 
 
Discussion 
 
 From genetic and in vitro studies, the transcriptional repressor Znf202 has been proposed 
as a key regulator of lipid homeostasis and in particular of lipid efflux 15. While its repressor 
function in vitro is well established, the precise role of Znf202 in lipid metabolism in vivo 
remains to be addressed. Using a gain of function approach involving adenoviral Znf202 gene 
transfer, we show in this study that hepatic Znf202 overexpression is accompanied by 
hypoalphalipoproteinemia both in WT and Ldlr-/- mice and by hypercholesterolemia and 
hypotriglyceridemia in Ldlr-/- only. Furthermore, in Ldlr-/- mice but not WT mice Znf202 
overexpression was found to promote steatosis.  
 Previous genetic studies have linked Znf202 to hypoalphalipoproteinemia in Utah 
pedigrees 4,7 while in in vitro studies Znf202 was reported to repress the expression of individual 
genes in the Apoe/c1/c2 and Apoa1/c3/a4/a5 cluster and ABC family members 5, suggesting a 
critical role of this protein in the regulatory control of HDL levels. Indeed, we show in this study 
that Znf202 overexpression in vivo does induce a large reduction of HDL levels both under 
normo- and hyper-lipidemic conditions.  
In vitro, we did find reduced expression of the apolipoprotein gene clusters by 30-50% by 
Ad-Znf202 in murine hepatoma mhAT3F2 cells (Vrins et al., manuscript in preparation), while 
Porsch-Ozcurumez et al. 16 found a reduction in human HepG2 cells of ABCA1 expression. Our 
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in vivo data, however, clearly indicate that no repression of the apoe/c1/c2 and Apoa1/c3/a4/a5 
and ABC family members is observed. 
The lack of correlation between the in vitro data and the gene expression profiles at 4 or 5 
days after adenoviral Znf202 administration might be caused by the induced initial changes in 
lipid homeostasis leading to secondary changes in lipid/fatty acid driven transcriptional factors 
like PPARs, LXRs, and FXR. Our aim was exactly to analyze the metabolic effect of an 
intervention in Znf202 expression and these secondary changes are thus the consequence of such 
a primary intervention. 
Our gene expression analysis revealed that at 4 and 5 days of Znf202 overexpression, an 
increased expression of Apoa5 and Apoc2 in both Ldlr-/- and WT mice was noticed. Both ApoA5 
and ApoC2 are intimately implicated in TG metabolism and specifically triacylglycerol 
hydrolysis (lipolysis). Studies by Schaap et al. 17, and by Pennacchio et al. 18, have demonstrated 
a clear inverse relationship between serum ApoA5 and VLDL-TG levels. Similarly, ApoC2 
functions as cofactor in LPL-mediated TG hydrolysis 19,20 and ApoC2 deficiency in humans is 
associated with severe hypertriglyceridemia 21. In line with these findings, Znf202 overexpression 
in Ldlr-/- mice indeed resulted in sharply reduced triglyceride levels compared to Ad-mock 
treated controls. Simultaneously, serum cholesterol levels increased 2-fold in LDLr-/- mice and 
this cholesterol was predominantly associated with the VLDL-sized lipoprotein fraction. A 
possible explanation for this phenomenon is that the increased rate of lipolysis results in an 
enhanced conversion rate of TG-rich VLDL to cholesterol-rich remnant particles, which can not 
be cleared in the absence of the LDLr and thus accumulate in the serum. The lack of this 
phenomenon in WT mice may stem from the fact that VLDL conversion and clearance are both 
operative and that additional effects of a further increased VLDL-TG lipolysis are not observed. 
Interestingly, previous studies with Apoa5 overexpression in WT mice showed a significant and 
dose-dependent decrease in serum HDL levels 17, which was also found in the present studies in 
both WT and LDLr-/- mice. 
In addition to the difference in serum lipids between both mouse strains, we observed an 
overt panlobular accumulation of TGs and cholesterol in Znf202 overexpressing livers of Ldlr-/- 
but not WT mice. Interestingly, the only effector gene to be differentially affected upon Znf202 
overexpression in WT versus LDLr-/- mice was Cyp7A1, which encodes a rate-limiting enzyme 
in bile acid synthesis. The selective Cyp7A1 upregulation in WT mice raises the intriguing 
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premise that Cyp7A1 may be instrumental in Znf202 induced responses. However, the 
mechanism of this confinement to WT mice and the regulatory pathway for the observed Cyp7A1 
upregulation remains to be elucidated. 
In conclusion we show for the first time that hepatic Znf202 overexpression affects lipid 
homeostasis in vivo, manifesting in hypoalphalipoproteinemia on the one hand, and, in the 
absence of the LDLr, in hypotriglyceridemia and steatosis on the other hand. The unaffected 
expression of the presumed Znf202 responsive genes at 4 and 5 days after adenoviral 
administration is unexpected given the demonstrated repressor function of Znf202 in in vitro 
studies in the literature 5,16 and also observed by our group (Vrins et al., manuscript in 
preparation). However, the induced gene expression of Apoa5 and Apoc2 can explain the 
observed changes in serum lipid profiles after Znf202 overexpression and thus form the final 
outcome of the increased Znf202 expression. This study thus establishes in vivo a key role of 
Znf202 in HDL metabolism and reveals Znf202 as novel target in maintaining lipid homeostasis. 
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Summary and Perspectives 
 
The liver plays a crucial role in the maintenance of serum lipoprotein levels. Therefore, 
treatment of hyperlipidemia via drug-induced alteration of lipid related gene expression in the 
liver is a rational approach. In this thesis the efficacy of influencing two new therapeutic targets 
was evaluated: the microsomal triglyceride transfer protein (MTP) for which the potential of 
inhibition by antisense based drugs was assessed and a new transcription factor Znf202 which is 
suggested to possess a widely applicable therapeutic potential. 
 
Antisense based drugs: specific targeting of MTP 
Since hepatic MTP is a rate-limiting enzyme in the production of the pro-atherogenic 
apoB100 containing lipoproteins such as VLDL and LDL (Hussain, 2003), the reduction of MTP 
expression via gene silencing could be an effective strategy to reduce elevated serum levels of 
VLDL and consequently LDL. In chapter 2 the design of a potent AS-ODN targeting muMTP is 
described. Although the reliability of computer-assisted secondary mRNA structure calculation is 
subject to debate, the use of such a method for finding suitable antisense sequences against 
muMTP was found to be successful with 50% of the designed AS-ODNs being effective in a cell-
free system. The use of a two-step evaluation strategy involving a cell free assay and a 
subsequent cellular read-out system based on an EGFP fusion construct, proved very effective 
and revealed AS569 as most potent antisense drug of the tested series with an IC50 of 15 nM. 
To increase the stability of AS-569 in a cellular environment phosphorothioate modified 
AS-ODN were used. Although this modification is widely applied, in agreement with previous 
studies we found that the administration of high concentrations of phosphorothioate modified 
ODNs is accompanied by non-target effects probably through aptameric interactions with cellular 
proteins 1,2. For example, non-sequence specific interactions with ribosomal proteins may affect 
mRNA translation. Recent advances in antisense drug design (e.g. PNAs) may improve the 
efficacy of antisense drugs and attenuate unfavorable side effects 3-5. In addition, conjugation of 
AS-ODNs to cell-surface receptor ligands or encapsulation/incorporation in (targeted) liposomes  
will help to further increase the specific delivery to target tissue 6-8.  Regardless of their 
chemistry, AS-ODNs will require repeated administration for sustained therapeutic activity due 
to their short-termed effect.  
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Amongst others, the advantage of ribozymes over AS-ODNs is that they are better fit for 
sustained intracellular production when introduced as ribozyme vectors and that they exhibit 
intrinsic endonuclease activity. When using ribozyme vectors time- and site-controlled 
expression and even co-localization of the ribozyme with its target mRNA can be effected by the 
choice of the right expression cassette. The cell-free screening assay developed in chapter 2 also 
proved useful in the design of ribozymes against muMTP described in chapter 3, as it allowed 
the identification of accessible regions within the muMTP mRNA. Based on the presence of 
cleavable GUX triplets we were able to track three possible targets within the muMTP mRNA: 
GUA342, GUC581, and GUC1802. During the development of the ribozyme constructs, a fourth, 
tandem ribozyme emerged as a result of head-to-tail ligation of two Rz581 units during the 
cloning process, RzT581. For in vitro analysis, the above mentioned two-step strategy was 
pursued. Target specific cleavage could be demonstrated for all four ribozymes in a cell-free 
system at which RzT581 proved to be considerably more potent than the other ribozymes. 
Conceivably this is caused  by the presence of an extra stem loop which on the one hand 
constrains the ribozyme transcript into a catalytically active configuration and on the other hand 
may render the ribozyme more stable against enzymatic degradation. These results and the 
finding that the targeted region (nt 581) was seen to be accessible for antisense based inhibition at 
a cellular level (chapter 2), led us to select Rz581 and RzT581 for subsequent adenovirus-
mediated ribozyme transfer.  
Cellular stability, the expression level, and intracellular distribution, which are governed 
by the promoter (pol II or pol III) and the ribozyme flanking sequences, are generally deemed to 
determine the efficacy of the ribozyme 9-12. Therefore, we generated a panel of adenoviral vectors 
at which the ribozyme is expressed from different expression cassettes. Indeed, our data 
demonstrate that the ribozyme-mediated reduction of cellular muMTP mRNA depends on the 
expression cassette used, and that the tRNAmet-expression cassette appears to be most suitable for 
further exploration of Rz581s potential in vivo.  
 
Znf202: a noval factor in lipid metabolism  
The search for promising therapeutic gene targets for hyperlipidemia has been aided 
considerably by investigations of the role of transcriptional regulators in lipid disorders. As 
discussed in chapter 1, nuclear receptors such as LXR, and the PPARs have received much 
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attention in this regard 13,14. Although its precise role in lipid metabolism has not yet been fully 
established, a new gene target in the regulation of lipid homeostasis is Znf202, a transcription 
factor that has recently been linked to hypoalphalipoproteinemia. In this thesis we first have 
characterized the repressive effect of Znf202 in vitro (chapter 4). After having demonstrated that 
the apoE/C1/C2 and apoA1/C3/A4/A5 gene clusters were affected by Znf202 overexpression in 
cultured mouse cells, we have investigated the Znf202-mediated downregulation of mouse apoE 
expression.  ApoE is an important protein in lipoprotein metabolism as it forms the recognition 
marker for chylomicron- and VLDL-remnant uptake from the blood circulation by the liver 15. 
The apoE promoter region directly upstream of the transcription initiation site, which is strongly 
conserved between mouse and human, was sufficient for repression of human apoE promoter 
activity by Znf202 16. While the extent of Znf202 repression of apoE expression between mouse 
and human was very similar, our studies revealed a species specific difference in the genetic 
architecture of the ApoE promoter with a Znf202 response region situated in a more upstream 
region containing two separate Znf202 binding motifs. Even though the in vitro data confirm the 
role of Znf202 as transcriptional regulator of essential lipid related genes, the latter finding can 
not rule out that species-specific differences exist in responsiveness to Znf202.  
Nevertheless, we clearly show in chapter 5 that Znf202 expression is linked with HDL 
serum levels and that Znf202 overexpression affects lipid metabolism. Furthermore, Znf202 
overexpression in vivo gave some surprising results in that it led to upregulation of two genes 
involved in lipolysis (Apoa5 and Apoc2) in both Ldlr-/- and wild type mice instead of the 
expected downregulation of several genes reported to be Znf202 responsive in vitro. The 
observed hypotriglyceridemia and increased levels of cholesterol-rich VLDL in Ldlr-/- 
overexpressing Znf202 can be attributed to an induced ApoA5 and ApoC2 expression 17,18.  The 
findings of Schaap et al. that HDL-levels were also lowered upon ApoA5 overexpression 18 may 
also point to a direct role of these two genes in Znf202 induced hypoalphalipoproteinemia in both 
mouse strains. Additionally, Znf202 overexpression was accompanied by induced expression of 
Cyp7A1, a key enzyme involved in bile acid synthesis, in wild type but not hyperlipidemic 
LDLr-/- mice.  As Znf202 overexpression induced steatosis in Ldlr-/- but not WT mice, the 
differential Cyp7A1 upregulation could be instrumental in intrahepatic lipid deposition after 
Znf202 overexpression. Although the altered gene expression profile caused by Znf202 
overexpression could at least partly explain the observed phenotypes, it still remains to be 
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clarified by which mechanism Znf202 is mediating these reponses. In this respect the analysis of 
the time dependent changes in liver gene expression upon adenoviral Znf202 administration may 
be informative. 
 
Conclusions and Perspectives 
 
Now the therapeutic potential of reducing MTP activity for the treatment of 
hyperlipidemia has been established 19,20 several MTP inhibitors have recently entered phase-II 
clinical trials. In one study, administration of an MTP inhibitor, CP-346086,  resulted in a 
significant reduction of total cholesterol and triglycerides in serum of human subjects 21. 
However, studies with these MTP inhibitors, liver specific knock-out mice, and findings 
observed in patients with abetalipoproteinemia have revealed potential adverse effects. These 
effects include fat accumulation in the liver and since current inhibitors do not discriminate 
between MTP function in intestine and liver, fat-soluble vitamin malabsorption, and steatorrhoea 
22,23. Thus, sequence specific MTP mRNA knockdown agents, delivered via liver specific 
vectors, could be a very attractive alternative approach to specifically lower hepatic MTP levels 
6,8,24. In this regard, the MTP mRNA reducing potential of the conventional antisense based 
AS569 (chapter 2) and ribozyme Rz581 (chapter 3) described in this thesis offer great promise in 
specific lowering of atherogenic apoB-containing lipoproteins. In addition, the identification of 
an effective target site within MTP mRNA also will facilitate the design of future short 
interfering RNA drugs, as also the latter drugs rely heavily on target RNA hybridization to be 
effective. The latter approach to knockdown gene expression has proven to be rather successful in 
vitro and in vivo. In fact, most, if not all, of the current attempts to reduce gene expression at a 
mRNA level are based on RNA interference (RNAi) 25.  This is further illustrated by a recent 
report that describes the RNAi-based intervention of the expression of apoB100 in vivo resulting 
in the reduction of apoB-containing serum lipoproteins 26.  
However, even though RNAi has rapidly evolved into the most common tool for target 
validation and therapeutic applications, this gene silencing technique also has its application 
problems. The major obstacle shared by all of the aforementioned strategies continues to be their 
effective targeting to the desired site of action in vivo. This is illustrated by a plethora of in vitro 
studies on antisense and gene silencing technology while only a limited number describe the 
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successful application in vivo 5,27. The poor applicability in vivo is partly attributable to low 
stability of these oligonucleotide drugs, to off-target effects and to unfavourable kinetics 28. As 
these hurdles are fundamentally similar to those encountered with antisense therapy, progress in 
RNAi drug design will certainly benefit from earlier experiences with the chemically related 
antisense drugs (e.g. stabilizing RNA chemistry, improvement of in vivo biodistribution and 
specific targeting adjustments.  
In conclusion, these antisense based methods for target validation have demonstrated 
potential effectivity and several antisense drugs already have entered clinical trials. Before 
widespread clinical application is possible the further development of effective site specific 
delivery will form a major challenge.  
 
In contrast to MTP, the therapeutic potential of the transcription factor Znf202 has to be 
further elucidated. In this thesis we have established that Znf202 expression is linked to 
hypoalphalipoproteinemia in vivo but also that Znf202 is involved in the regulatory control of 
hepatic lipid homeostasis and, possibly, in hyperlipidemia associated steatosis. While it is 
tempting to regard Znf202 as an attractive target for therapeutic intervention in 
hypoalphalipoproteinemia and, more in general, in hyperlipidemia, one should be cautious with 
extrapolating the data to clinical practice. Further investigation will be needed to fully 
comprehend the regulatory pathways induced by Znf202 expression modulation and the 
interaction of Znf202 with other hepatic transcription factors. In this regard, it will certainly be 
relevant to compare phenotypic effects of Znf202 overexpression in LDLr-/- mice (chapter 5) 
with that of ApoA5, thus establishing that ApoA5 links Znf202 with hypoalphalipoproteinemia. 
A second important actor in Znf202 induced responses in vivo is Cyp7A1 and it will be of 
interest to investigate the relation between Znf202 and bile acid related pathways. Recent reports 
have pointed out that activation of FXR-mediated pathways is accompanied by an upregulation 
of lipolysis related genes such as Apoc2 30,31 and Apoa5 32. Under hyperlipidemic conditions 
Znf202 may influence bile acid synthesis indirectly through cyp7A1 leading to excessive hepatic 
bile acid accumulation which, eventually, via FXR mediated compensatory feedback regulation 
of cyp7A1, culminates in lowered serum TG levels and steatosis 33. However, this hypothesis 
needs to be further explored and further work is needed to fully understand the phenotypic effects 
observed by Znf202 expression modulation.  
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Transcription factor Znf202.  Znf202 homodimers bind to 
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 the GnT consensus site in the promoter region and initiate 
transcriptional silencing mechanisms. 29. In vivo experiments 
show that hepatic overexpression of Znf202 results in reduced 
HDL-levels and affects genes involved in bile acid synthesis 
(cyp7A1) and lipolysis (apoA5 and apoC2). 
 
 
 
 
 
 
 
In addition, the relevance of the naturally occurring splice variant of Znf202 (M3), 
ontaining only the SCAN oligomerization domain needs to be addressed 16. Evidence for 
CAN-mediated interaction between SCAN-containing proteins has been presented 34 and other 
CAN-only proteins such as the PPARγ co-activator SDP-1 have been characterized 35. The 
inding that SDP-1 not only is involved in the PPARγ pathway, but also binds Znf202 strongly 
uggests a tight link between these two transcription factors. As for now the actual function of 
3 (i.e. antagonist versus inert decoy) remains unclear. However, our preliminary results with 
3 adenovectors did not reveal any effect of M3 on the activity of full length Znf202 or its 
ownstream target genes, pleading for the option that M3 is an inert decoy.  
Because of the apparently broad role of Znf202 a subtle therapeutic approach based on 
odulation Znf202 expression might be difficult to achieve. However, better understanding of 
he Znf202 pathway will contribute to more insight in its potential and might lead to the 
dentification of new targets for therapeutic gene modulation. 
In general, modulation of hepatic gene expression holds great promise as therapeutic 
pproach to restore/correct lipid homeostasis. However, therapeutic interference in gene 
xpression levels requires a thorough understanding of the impact of the change in expression of 
he primary gene on total metabolism. The aim of therapeutic gene expression either by antisense 
ligonucleotides, ribozymes, or other antisense based strategies requires effective delivery to the 
pecific intracellular action site. These are essential steps needed for future applications of the 
ene targeted correction of hyperlipidemia in clinical settings. 
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 Momenteel vormen hart- en vaatziekten de belangrijkste doodsoorzaak in de westerse 
samenleving. Voor een groot deel is dit een gevolg van een sterke vernauwing van de bloedvaten, 
ook bekend onder de naam atherosclerose. Diverse risikofactoren zijn geïdentificeerd die 
bijdragen tot een versnelde vernauwing van de bloedvaten, zoals een verhoogd cholesterol- en 
triglyceridengehalte in het bloed. 
Vetten (lipiden) zoals cholesterol en triglyceriden zijn belangrijk voor het normaal functioneren 
van ons lichaam. Ze vormen een noodzakelijke grondstof voor de energievoorziening en zijn 
belangrijk voor de aanmaak van hormonen en de opbouw van celmembranen. Naast de opname 
van lipiden via voeding, is ons lichaam ook zelf in staat om lipiden aan te maken (biosynthese) en 
dit vindt voornamelijk plaats in de lever. Een overgroot deel van de dagelijks benodigde 
hoeveelheid cholesterol is zelfs afkomstig uit de biosynthese. 
Omdat lipiden slecht in een waterig mileu, zoals bloed, oplossen, worden ze naar de 
verschillende weefsels en organen van het lichaam getransporteerd via bolvormige deeltjes –  de 
lipoproteïnen. Deze lipoproteïnen bestaan naast lipiden tevens uit eiwitten genaamd 
apolipoproteïnen. Op basis van de samenstelling van lipiden en apolipoproteïnen kunnen er 
verschillende soorten lipoproteïnen onderscheiden worden: chylomicronen, zeer lage dichtheids- 
(VLDL), lage dichtheids- (LDL) en hoge dichtheids-lipoproteïnen (HDL). Over het algmeen kan 
men stellen dat chylomicronen, VLDL en LDL lipiden transporteren naar alle delen van het 
lichaam, terwijl HDL het overtollige cholesterol opneemt en vervolgens transporteert naar de 
lever. 
Onder normale omstandigheden bestaat er een evenwicht tussen de aanmaak en opname 
van lipiden enerzijds en de hoeveelheid die verbruikt of verwijderd wordt anderzijds. Dit 
evenwicht is bepalend voor de totale concentratie lipiden in het bloed en de verdeling hiervan 
over de verschillende lipoproteïnen. De lever speelt in dit proces van lipide-stofwisseling (-
metabolisme) een belangrijke rol. Een verstoring van het evenwicht in het lipidemetabolisme kan 
leiden tot een verhoogde bloedspiegel van lipiden genaamd: hyperlipidemia. Een verhoging van 
de lipide-transporterende deeltjes VLDL en LDL, kan de atherosclerotische vaatvernauwing 
aanzienlijk versnellen en deze lipoproteïnen worden daarom dan ook vaak aangeduid als het 
‘slechte cholesterol’. De oorzaak voor dit verstoorde evenwicht is deels een gevolg van de 
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westerse levenstijl die in het algemeen gepaard gaat met een te vetrijk dieet en/of te weinig 
lichaamsbeweging. Echter, mensen kunnen ook een erfelijke aanleg hebben voor hyperlipidemia. 
In hoofdstuk 1 wordt een overzicht gegeven van het lipidemetabolisme en de centrale rol die de 
lever hierin speelt. 
 
Dit project beoogde gen-therapeutische strategieën te ontwikkelen teneinde de 
bloedspiegelniveau’s van de vet-transporterende deeltjes gunstig te beïnvloeden en daarmee de 
ontwikkeling van hart- en vaatziekten af te remmen. Hierbij hebben we ons onderzoek gericht op 
twee sleutelmoleculen: het microsomale triglyceride transfer eiwit (MTP) dat verantwoordelijk is 
voor de aanmaak van schadelijke lipoproteïnen (VLDL) in de lever en een recent ondekte 
genregulerende factor Znf202, waarvan onderzoek heeft aangetoond dat het de bloedspiegel van 
het beschermende HDL beïnvloedt. 
In eerste instantie is getracht een nieuwe vorm van gentherapie uit te werken, waarbij het 
mRNA van het MTP-gen afgebroken wordt teneinde de aanmaak van MTP te verlagen. In 
hoofdstuk 2 wordt de ontwikkeling van MTP antisense moleculen beschreven. Antisense-DNA 
is een klein stukje complementair DNA dat selectief bindt aan het mRNA van een bepaald gen en 
daarmee de vertaling van dit gen naar het corresponderende eitwit blokkeert (zie tekstbox). 
Hoewel we theoretisch tegen elke mRNA antisense-DNA kunnen ontwerpen dat de vertaling zal 
blokkeren, blijkt het ontwerp van een effectief antisense-DNA in de praktijk erg lastig. Dit komt 
met name omdat mRNA moleculen zijn opgevouwen tot een complexe kluwen, zodat sommige 
delen van mRNA niet toegankelijk zijn voor binding van het antisense-DNA. Er bestaan wel 
computerprogramma’s waarmee de opvouwing van het RNA en daarmee de domeinen die 
beschikbaar zijn voor binding, voorspeld kunnen worden, maar dergelijke berekeningen zijn niet 
altijd volledig betrouwbaar. Daarom worden vaak meerdere antisense-DNAs ontworpen die elk 
op verschillende plekken van het mRNA aangrijpen. Deze antisense-DNAs moeten dan 
vervolgens getest worden op hun effectiviteit. Omdat dit laatste een tijdrovend proces kan zijn, 
hebben wij een nieuwe doeltreffende selectiemethode ontwikkeld en getoetst. 
Nadat er via de voorspelde MTP mRNA-opvouwing twaalf antisense-DNA kandidaten 
waren onworpen, werden deze antisense-DNAs op hun activiteit getest in een zogeheten celvrij 
transcriptie-translatie systeem. Middels dit systeem, dat de vertalingsreactie van het MTP-gen via 
mRNA naar eiwit kunstmatig nabootst, kon snel gescreened worden welke MTP antisense-DNAs 
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e genoom bestaat uit ongeveer 30.000 genen en iedere cel in het menselijk lichaam bezit een
t totale erfelijke materiaal. De genen zijn verdeeld over 46 DNA-ketens (chromosomen) die
rn van de cel bevinden en coderen voor de aanmaak van functionele moleculen die bekend
tten. Van elk gen dat afgelezen wordt, wordt eerst een tussenkopie gemaakt, messenger RNA
rlijk vertaald boodschapper RNA). Dit mRNA wordt vervolgens uit de celkern naar een het
etransporteerd waar het vertaald wordt in eiwit. Als gevolg van mutaties in genen kunnen
 onstaan doordat bijvoorbeeld foutieve eiwitten aangemaakt worden of doordat de aanmaak
Sinds het genetische materiaal van de mens in kaart gebracht is, is een therapie waarbij de
eïnvloed worden steeds meer in de belangstelling gekomen. ef waren. Uit dit experiment bleek dat zes van de twaalf antisense-DNAs (50%) in 
 de expressie van het MTP te remmen. Echter, een potentiele kandidaat voor 
et tevens werkzaam zijn in het meer complexe mileu van een cel. Om evaluatie 
eutische activiteit van het geselecteerde MTP antisense-DNA in de cel te 
, werd gebruik gemaakt van een nieuw uitleessysteem op basis van een 
iwit uit de kwal (green fluorescent protein, GFP). Door het MTP-gen te koppelen 
n en het fusie-eiwit MTP-GFP vervolgens in de testcel tot expressie te brengen, is 
 intensiteit van de groene fluorescentie in de cel als maat te gebruiken voor de 
Nederlandse Samenvatting 
aanwezige hoeveelheid MTP. Met deze proefopzet konden we aantonen dat het MTP antisense-
DNA, AS-569, ook in een cellulair milieu condities effectief in staat was om de MTP expressie te 
remmen. 
Naast deze antisense techniek hebben we in hoofdstuk 3 ook een tweede strategie 
bestudeerd om de expressie van MTP te verlagen. In ribozym therapie wordt gebruik gemaakt 
van een klein, enzymatisch actief RNA fragment, dat niet vertaald wordt naar eiwit, en dat hecht 
aan een gedefiniëerd gebiedje op het mRNA volgens dezelfde beginselen als antisense-DNA. 
Echter, door de aanwezigheid van het enzymatisch domain, is het ribozym in staat om het mRNA 
op de plek van binding in tweeën te knippen en het mRNA vervolgens weer los te laten. Een 
ribozym biedt dus het voordeel dat het meerdere mRNA kopiën van een gen onwerkzaam kan 
maken. Omdat de ribozym-binding ook berust op de interactie met toegankelijke regionen binnen 
het mRNA, konden we voor het ontwerp van het MTP ribozym gebruik maken van de resultaten 
uit hoofdstuk 2. Er is een reeks ribozymen gemaakt en getest op de capaciteit om MTP mRNA te 
splitsen in een celvrij systeem. Het MTP specifieke ribozyme Rz581 en met name een tandem 
versie van dit Rz581 (twee Rz581 aan elkaar gekoppeld) bleken daarbij de hoogste activiteit te 
bezitten. Omdat ribozymen bestaan uit RNA (vergelijkbaar met mRNA),  kunnen ze vanuit een 
‘ribozym-gen’ door de cel zelf geproduceerd worden. Het meest actieve ribozym-gen werd 
ingebouwd in een defect adenovirus (een verkoudheidsvirus dat niet meer in staat is om zich te 
vermenigvuldigen), dat de capaciteit bezit om ingebouwde genen, dus ook ribozym-genen, heel 
efficiënt aan levercellen af te leveren. Daarbij is een serie adenovirussen geconstrueerd waarbij 
de aanmaak van het ribozym gereguleerd werd door diverse promoteren (CMV, snRNA-U6 en 
tRNAmet). Een promoter, die aan het begin van een gen gelegen is (zie tekstbox), is de 
belangrijkste regulator van de gen-activiteit. Elke promoter bevat eigenschappen die nodig zijn 
om de expressie van zijn bijbehorende gen te controleren. Sommige promotoren (zoals de van 
een virus afkomstige CMV promoter) staan vaker ‘aan’ dan andere, enkele promotoren (zoals die 
voor snRNA-U6 en tRNAmet) zijn speciaal toegerust voor de transcriptie van kleine RNA-
fragmenten zoals ribozymen, en promotoren kunnen mede bepalen in welk deel van de cel (kern 
of cytoplasma) het mRNA getransporteerd moet worden. In levercellen bleek uiteindelijk dat 
Rz581-adenovirussen voorzien van een tRNAmet promoter effectief in staat waren de synthese 
van het MTP te remmen.
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De veelbelovende resultaten met zowel het antisense-DNA (AS-569) als het ribozym 
(Rz581) tegen MTP bieden mogelijkheden om een gerichte therapie te ontwikkelen die de 
bloedspiegel van VLDL en LDL doen verlagen. Evaluatie van deze kandidaat geneesmiddelen in 
diermodellen zal zijn nu nodig zijn om hun medicinale werking en eventuele bijwerking te 
toetsen. 
 
In een tweede onderzoekslijn is de rol van het regulatoir sleuteleiwit Znf202 in het lipide-
metabolisme en zijn potentiele waarde als aangrijppunt voor (gen)therapie bestudeerd. Recent is 
met behulp van genetisch onderzoek een verband gevonden tussen een tot dan toe nog onbekend 
gen Znf202 en een specifieke groep patienten die gekenmerkt worden door een te lage 
bloedspiegel van HDL en daarmee een verhoogde kans hebben op hart- en vaatziekten. HDL is 
een essentieel lipoproteïne dat er voor zorgt dat een teveel aan cholesterol afgevoerd kan worden 
naar de lever waarna het eventueel afgebroken en verwijderd kan worden en wordt daarom ook 
vaak aangeduid als het ‘goede cholesterol’. Uit vervolgonderzoek bleek dat Znf202 codeert voor 
een transcriptie factor die door binding aan de promoter van andere genen de expressie van deze 
genen kan verlagen. Interessant was hierbij dat de genen die mogelijk gecontroleerd worden door 
Znf202 allen betrokken zijn bij het lipide-metabolisme. Echter, vanwege de verschillende 
functies die de genen hebben in het lipide-metabolisme, is het moeilijk in te schatten wat het 
algehele effect van modulatie van de Znf202 activiteit is.  
Om antwoord te vinden op de bovengenoemde vraag hebben we het effect van 
overproductie van Znf202 zowel in vitro (levercellen) als in vivo (overproductie in de lever van 
muizen) onderzocht. Hiertoe is er een adenovirus geproduceerd dat het Znf202 gen bevat – Ad-
Znf202. In hoofdstuk 4 wordt beschreven dat Ad-Znf202 in staat is de expressie van een groot 
aantal belangrijke apolipoproteïne-genen in levercellen te verlagen, waaronder het 
apolipoproteïne E (apoE) gen. Met behulp van promoter-studies voor apoE expressie kon 
aangetoond worden dat Znf202 aangrijpt op de expressie door binding aan specifieke domeinen 
in het promotergedeelte, waarbij de expressie wordt geremd.  
Vervolgens werd in vivo het effect bestudeerd van de expressie van Znf202 op het lipide-
metabolisme (Hoofdstuk 5). Adenoviraal gemedieerde expressie leidt tot effectieve expressie in 
de lever. Hierbij werden zowel muizen met een normale lipide-bloedspiegel, als genetisch 
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gemodificeerde muizen (Ldlr-/- muizen) met een verhoogde lipide-bloedspiegel en gevoeligheid 
voor atherosclerose gebruikt. 
De overproductie van Znf202 in de Ldlr-/- muizen resulteerde in een sterke verandering in 
de totale lipide-bloedspiegel en de verdeling van deze lipiden over de verschillende 
lipoproteinen; corresponderend met een sterke toename van het ‘slechte cholesterol’. Tevens 
leidde overproductie tot een dramatische vervetting van de lever (steatose). Op het gebied van 
genactiviteit in de lever werd een verhoging in expressie van een aantal apolipoproteïne genen 
geïnduceerd. Dat laatste was zeer verrassend, aangezien onderzoek in vitro, zoals beschreven in 
hoofdstuk 4, een remmend effect van Znf202 op genactiviteit laat zien. Het effect van Znf202 
overproductie bij controle muizen was duidelijk milder met nagenoeg geen veranderingen in de 
lipide-bloedspiegel en geen waarneembare steatose. Wel werd een duidelijke opregulatie van 
dezelfde apolipoproteïne genen als in Ldlr-/- muizen waargenomen. Daarnaast werd een zeer 
sterke verhoging van een eiwit dat betrokken is bij de afbraak van cholesterol in de lever 
aangetroffen, wat misschien tevens een verklaring is voor de mildere effecten in controle muizen. 
Een belangrijke waarneming in beide muizen was dat als gevolg van Znf202 overproductie, de 
HDL-bloedspiegels sterk afnamen. Dit bevestigt dat Znf202 de HDL-bloedspiegels reguleert en 
dat verlaging van HDL het gevolg kan zijn van verhoogde activiteit van Znf202.  
Deze in vivo studie toont voor het eerst aan dat Znf202 in de lever vooral onder condities 
van een verstoorde lipidemetabolisme (Lldr-/- muizen) een zeer belangrijke regulerende factor 
betreft. Met betrekking tot het verbeteren van HDL-bloedspiegels lijkt remming van Znf202 dan 
ook een relevante en veelbelovende therapeutische ingang ter behandeling van patiënten met een 
verstoorde lipidehuishouding. Echter, in hoeverre remming van Znf202 klinisch perspectiefvol is, 
moet blijken uit nieuwe experimenten met bijvoorbeeld Znf202-specifieke antisense-DNA of 
ribozymen. 
 
De identificatie van genen in de lever die betrokken zijn bij de regulatie van het lipide-
metabolisme, geven een beter inzicht in de oorzaken en mechanismen van hart-en vaatziekten. 
Dit onderzoek leidt daarmee tot nieuwe therapeutisch mogelijkheden om deze ziekten te 
behandelen en te voorkomen. In dit proefschrift worden twee fundamentele trajecten beschreven 
in het onderzoek naar de perspectieven van levergerichte gentherapie ter correctie van 
hyperlipidemia: een gentherapeutische strategie ter modulatie van de expressie van een overactief 
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en/of ziektebevorderend gen (MTP) en de verkenning naar therapeutische mogelijkheden van een 
recent geïdentificeerde genregulator (Znf202). Van het MTP-gen heeft eerder onderzoek al laten 
zien dat het een cruciale rol heeft in de aanmaak van slecht cholesterol. Met behulp van antisense 
technieken zoals onder andere beschreven in hoofdstuk 2 en 3 kunnen we heel specifiek het gen 
(tijdelijk) uit schakelen om zo weer een gunstig evenwicht te creëren in de lipide-bloedspiegel. In 
de hoofdstukken 4 en 5 laten we zien dat Znf202 een grote rol speelt in lpidehuishouding en de 
HDL-niveaus in het bloed reguleert. Toekomstig onderzoek zal moeten uitwijzen of correcties in 
Znf202 activiteit een gunstig effect kan hebben op patienten met een verstoord vet-metabolisme. 
Omdat genen tot de fundamentele bouwstenen van ons lichaam behoren, is het natuurlijk 
vanzelfsprekend dat elke ingreep op genniveau goed bestudeerd moet worden alvorens van 
klinische toepassing sprake kan zijn. Echter, samen met de ontwikkeling van strategiën voor de 
lokale toediening van medicijnen, kan een dergelijke therapeutische benadering binnen de 
geneeskunde leiden tot een nieuwe generatie geneesmiddelen ter voorkoming en/of bestrijding 
van hart- en vaatziekten. 
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